Page last updated: 2024-12-04

1,3-dipropyl-8-cyclopentylxanthine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

You're likely asking about **1,3-dipropyl-8-cyclopentylxanthine** (DPCPX), not 1,3-dipropyl-8-cyclopentylxanthine. This is a very important compound in research, particularly in the fields of **neuroscience and pharmacology**.

Here's why:

* **It's a selective adenosine A1 receptor antagonist.** This means it specifically blocks the action of adenosine at the A1 receptor, a key type of receptor in the brain and other tissues.

* **Adenosine A1 receptors are involved in many important physiological processes:**
* **Neurotransmission:** They regulate neuronal activity, influencing sleep, wakefulness, attention, and memory.
* **Cardiovascular function:** They control heart rate and blood pressure.
* **Inflammation:** They modulate the immune system and inflammatory responses.
* **Renal function:** They influence kidney function and fluid balance.

* **DPCPX is a valuable tool for researchers:**
* **Understanding the role of adenosine A1 receptors:** By blocking these receptors, scientists can investigate their specific contributions to various processes.
* **Developing new drugs:** DPCPX serves as a lead compound for creating drugs that target the A1 receptor. This could lead to new treatments for conditions like anxiety, insomnia, epilepsy, and heart disease.

**Here's a simplified analogy:** Imagine adenosine as a key that activates a certain lock (the A1 receptor). DPCPX acts like a plug that fits into the keyhole but doesn't open the lock, preventing adenosine from activating the receptor.

**In summary, DPCPX is a powerful research tool used to understand the role of adenosine A1 receptors and to develop new drugs that target these receptors.**

DPCPX : An oxopurine that is 7H-xanthine substituted at positions 1 and 3 by propyl groups and at position 8 by a cyclohexyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID1329
CHEMBL ID183
CHEBI ID73282
SCHEMBL ID1094807
SCHEMBL ID382422
SCHEMBL ID12648692
MeSH IDM0146212

Synonyms (116)

Synonym
LS-14528
MLS001076525
HMS3266O21
BRD-K01824921-001-02-9
gtpl386
smr000058434
KBIO1_000177
DIVK1C_000177
pd-116948
EU-0100381
8-cyclopentyl-1,3-dipropylxanthine, solid
SPECTRUM_000271
1,3-dpcpx
pd-116,948
1h-purine-2,6-dione, 8-cyclopentyl-3,7-dihydro-1,3-dipropyl-
8-cyclopentyl-3,7-dihydro-1,3-dipropyl-1h-purin-2,6-dione
[dpcpx]
1,3-dipropyl-8-cyclopentylxanthine
lopac-c-101
tocris-0439
NCGC00023294-02
NCGC00015177-01
PDSP2_001192
BSPBIO_002686
PDSP1_000448
SPECTRUM5_001887
LOPAC0_000381
PDSP2_000446
IDI1_000177
PDSP1_001208
BCBCMAP01_000212
102146-07-6
8-cyclopentyl-1,3-dipropylxanthine
chembl183 ,
pd116948 ,
bdbm21173
8-cyclopentyl-1,3-dipropyl-2,3,6,7-tetrahydro-1h-purine-2,6-dione
dpcpx
NCGC00023294-05
NCGC00023294-07
MLS000069347 ,
KBIOGR_001696
KBIOSS_000751
KBIO2_000751
KBIO2_003319
KBIO2_005887
KBIO3_001906
SPECTRUM3_001073
SPECTRUM4_001228
SPECTRUM2_001808
NINDS_000177
SPBIO_001795
SPECTRUM2300063
NCGC00015177-02
NCGC00023294-04
NCGC00023294-06
NCGC00015177-06
dpcpx; pd 116,948
NCGC00015177-11
chebi:73282 ,
gnf-pf-2224 ,
L000233
HMS500I19
8-cyclopentyl-1,3-dipropyl-7h-purine-2,6-dione
HMS3261M03
EX-3308
8-cyclopentyl-1,3-dipropyl-1h-purine-2,6(3h,7h)-dione
HMS2235C14
dipropylcyclopentylxanthine
8-cyclopentyl-1,3-dipropyl-3,7-dihydro-1h-purine-2,6-dione
CCG-39732
NCGC00015177-09
NCGC00015177-07
NCGC00015177-05
NCGC00015177-08
NCGC00015177-10
NCGC00015177-04
NCGC00015177-03
unii-9ptp4foi9e
9ptp4foi9e ,
FT-0621530
LP00381
AKOS015900114
HMS3369D05
CCG-221685
pd 116,948
FFBDFADSZUINTG-UHFFFAOYSA-N
SCHEMBL1094807
NCGC00261066-01
tox21_500381
SCHEMBL382422
W-200660
SCHEMBL12648692
1,3-dipropyl-8-cyclopentylxanthine [dpcpx]
AKOS024458134
OPERA_ID_160
DTXSID50144706
mfcd00055117
8-cyclopentyl-1,3-dipropylxanthine [dpcpx]
sr-01000003000
SR-01000003000-2
SR-01000075202-1
sr-01000075202
A16104
DB12946
Q5280076
HB2094
EX-A7108
HMS3675K21
HMS3411K21
BRD-K01824921-001-10-2
SDCCGSBI-0050368.P003
NCGC00015177-16
CS-0020608
HY-100937
GLXC-25218

Research Excerpts

Effects

ExcerptReferenceRelevance
"1,3-dipropyl-8-cyclopentylxanthine (CPX) has been shown to stimulate in vitro CFTR activity in F508 cells. "( Physical Characterization of 1,3-dipropyl-8-cyclopentylxanthine (CPX).
Kolling, W; Li, T; Long, S; Manek, RV; McPherson, T, 2010
)
2.09

Pharmacokinetics

ExcerptReferenceRelevance
" We identify compounds with significantly improved bioactivity (approximately 40-fold) against replication of the infectious prion isoform (PrPSc) and suitable pharmacokinetic profiles to warrant evaluation in animal models of prion disease."( Structure-activity relationship study of prion inhibition by 2-aminopyridine-3,5-dicarbonitrile-based compounds: parallel synthesis, bioactivity, and in vitro pharmacokinetics.
Cohen, FE; Legname, G; May, BC; Prusiner, SB; Sherrill, J; Wallace, AC; Witkop, J; Zorn, JA, 2007
)
0.34

Bioavailability

ExcerptReferenceRelevance
" In addition, this series of compounds has demonstrated good bioavailability and in vivo efficacy in a rodent model of Parkinson's disease, despite having reduced potency for the rat A2A receptor versus the human A2A receptor."( Identification of novel, water-soluble, 2-amino-N-pyrimidin-4-yl acetamides as A2A receptor antagonists with in vivo efficacy.
Castro-Palomino, JC; Chen, Y; Crespo, MI; Díaz, JL; Gross, RS; Gual, S; Joswig, T; Lanier, MC; Lechner, SM; Lin, E; Malany, S; Markison, S; Moorjani, M; O'Brien, Z; Prat, M; Rueter, JK; Santos, M; Saunders, J; Slee, DH; Wen, J; Williams, JP; Zhang, X, 2008
)
0.35
" Data from a phase I study demonstrated erratic bioavailability and no measurable clinical response to oral CPX."( Physical Characterization of 1,3-dipropyl-8-cyclopentylxanthine (CPX).
Kolling, W; Li, T; Long, S; Manek, RV; McPherson, T, 2010
)
0.65
" The orally bioavailable lead imidazolopiperazine confers complete causal prophylactic protection (15 milligrams/kilogram) in rodent models of malaria and shows potent in vivo blood-stage therapeutic activity."( Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.
Barnes, SW; Bonamy, GM; Bopp, SE; Borboa, R; Bright, AT; Chatterjee, A; Che, J; Cohen, S; Dharia, NV; Diagana, TT; Fidock, DA; Froissard, P; Gagaring, K; Gettayacamin, M; Glynne, RJ; Gordon, P; Groessl, T; Kato, N; Kuhen, KL; Lee, MC; Mazier, D; McNamara, CW; Meister, S; Nagle, A; Nam, TG; Plouffe, DM; Richmond, W; Roland, J; Rottmann, M; Sattabongkot, J; Schultz, PG; Tuntland, T; Walker, JR; Winzeler, EA; Wu, T; Zhou, B; Zhou, Y, 2011
)
0.37
", ip) indicate that the liver is the primary site of biotransformation of the compound, suggesting that both 22a and its metabolite(s) are active, compensating probably low bioavailability of the parent molecule."( Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.
Bednarski, M; Gunia-Krzyżak, A; Marona, H; Nitek, W; Pękala, E; Powroźnik, B; Słoczyńska, K; Walczak, M; Waszkielewicz, AM; Żesławska, E, 2016
)
0.43

Dosage Studied

ExcerptRelevanceReference
" CGS 15943 (100 nM), a nonselective adenosine antagonist, attenuated the VR activity of DPMA and CPA, causing a 9- and 12-fold rightward shift of the dose-response curves, respectively, whereas 8-cyclopentyl-1,3-dipropylxanthine (20 nM), a highly A1-selective blocker, had no such effect."( Demonstration of vasorelaxant activity with an A1-selective adenosine agonist in porcine coronary artery: involvement of potassium channels.
Cox, BF; Lappe, RW; Merkel, LA; Perrone, MH; Rivera, LM, 1992
)
0.28
" The selective A1 receptor antagonist DPCPX also had no effect on release when administered at a low dosage (0."( Excitatory transmitter amino acid release from the ischemic rat cerebral cortex: effects of adenosine receptor agonists and antagonists.
O'Regan, MH; Perkins, LM; Phillis, JW; Simpson, RE, 1992
)
0.28
" After control responses to these purinergic agonists were elicited, animals were given infusions for several hours of either vehicle or one of six dosage levels of FK453 (a potent, selective, nonxanthine A1 receptor antagonist), one of three dosage levels of FR113452 (the S-enantiomer of FK453) or one of seven dosage levels of DPCPX (a potent, selective, xanthine A1 receptor antagonist)."( An experimental paradigm for investigating the role of endogenous adenosine/A1 receptor interactions in vivo.
Herzer, WA; Jackson, EK; Kuan, CJ, 1992
)
0.28
" Increasing concentrations of the highly selective adenosine A1 receptor antagonist 1,3-dipropyl-8-cyclopentylxanthine (DPCPX, 3-100 nM) produced parallel, rightward shifts of the dose-response curve for the N6-cyclopentyladenosine (CPA)-induced decrease in PS amplitude."( Adenosinergic inhibition in hippocampus is mediated by adenosine A1 receptors very similar to those of peripheral tissues.
Alzheimer, C; Kargl, L; ten Bruggencate, G, 1991
)
0.51
" The dose-response curve was shifted to the left by factor 30 in diabetic, compared with nondiabetic rats rats."( Increased sensitivity of the renal vasculature to adenosine in streptozotocin-induced diabetes mellitus rats.
Osswald, H; Pflueger, AC; Schenk, F, 1995
)
0.29
"05) shifting the dose-response curve to the right."( Adenosine-induced bronchoconstriction and contraction of airway smooth muscle from allergic rabbits with late-phase airway obstruction: evidence for an inducible adenosine A1 receptor.
Ali, S; Metzger, WJ; Mustafa, SJ, 1994
)
0.29
" When measured in the presence of antagonists, the dose-response curves of NECA-induced inhibition of forskolin-stimulated cAMP accumulation were right-shifted."( Molecular cloning and characterization of the human A3 adenosine receptor.
Jacobson, MA; Johnson, RG; Linden, J; Salvatore, CA; Taylor, HE, 1993
)
0.29
" In a dose-response relationship for ATP, adenosine A1 receptor activation shifted the half-maximal inhibition of the KATP channel from 70 to 241 microM."( Modulation of ATP-sensitive K+ channels in rabbit ventricular myocytes by adenosine A1 receptor activation.
Earm, YE; Han, J; Ho, W; Kim, E, 1997
)
0.3
" Dose-response studies revealed region-specific differences in the magnitude of A1 receptor-stimulated G-protein activation, with the highest response (nine-fold over basal) detectable in the hippocampus."( Selective detection of adenosine A1 receptor-dependent G-protein activity in basal and stimulated conditions of rat brain [35S]guanosine 5'-(gamma-thio)triphosphate autoradiography.
Laitinen, JT, 1999
)
0.3
" The ET-1 dose-response curve (1 pM-5 nM) was rightward shifted after preconditioning with adenosine (1 microM) for 20 min and 10 min of washout (n = 11)."( Adenosine preconditions against endothelin-induced constriction of coronary arterioles.
Chilian, WM; Jones, DW; Merkus, D; Nishikawa, Y; Stepp, DW, 2000
)
0.31
" Efficacy was determined using nasal transepithelial potential difference and sweat chloride measurements prior to dosing and at 1, 2, and 4 hr postdose."( A phase I randomized, multicenter trial of CPX in adult subjects with mild cystic fibrosis.
Ahrens, RC; Aitken, ML; Hilliard, KA; Kelley, TJ; Konstan, MW; Launspach, J; McCarty, NA; Milgram, LJ; Regelmann, WE; Standaert, TA; Teresi, M; Tuthill, C; Weatherly, MR, 2002
)
0.31
" In slices from heterozygous mice the dose-response curve for both adenosine and ATP was shifted to the right."( Modulation of hippocampal glutamatergic transmission by ATP is dependent on adenosine a(1) receptors.
Diao, L; Dunwiddie, TV; Fredholm, BB; Illes, P; Johansson, B; Larson, GA; Masino, SA; Zahniser, NR, 2002
)
0.31
" The genistein dose-response curve was bell-shaped due to inhibitory activity at the highest concentrations."( Correction of G551D-CFTR transport defect in epithelial monolayers by genistein but not by CPX or MPB-07.
Becq, F; Cabrini, G; Caci, E; Fanen, P; Folli, C; Galietta, LJ; Mettey, Y; Romio, L; Vierfond, JM; Zegarra-Moran, O, 2002
)
0.31
"0 mg/ml) resulted in tolerance to the motor effects of an acute administration of caffeine, lack of tolerance to amphetamine, apparent tolerance to MSX-3 (shift to the left of its 'bell-shaped' dose-response curve), and true cross-tolerance to CPT."( Involvement of adenosine A1 and A2A receptors in the motor effects of caffeine after its acute and chronic administration.
Antoniou, K; Ferré, S; Fuxe, K; Goldberg, SR; Justinova, Z; Karcz-Kubicha, M; Müller, CE; Pezzola, A; Popoli, P; Quarta, D; Reggio, R; Solinas, M; Terasmaa, A, 2003
)
0.32
" Morphine and R-PIA were administered to obtain the dose-response curve and the 50% effective dose (ED(50))."( Morphine can enhance the antiallodynic effect of intrathecal R-PIA in rats with nerve ligation injury.
Cho, SK; Han, SM; Hwang, GS; Hwang, JH, 2005
)
0.33
"11 for mutant F84L to 999 for two highly constitutively active mutants yielded simulated dose-response curves that mimicked the experimental curves."( ZM241385, DPCPX, MRS1706 are inverse agonists with different relative intrinsic efficacies on constitutively active mutants of the human adenosine A2B receptor.
Beukers, MW; Blad, CC; Brouwer, J; den Dulk, H; Ijzerman, AP; Li, Q; Ye, K, 2007
)
0.34
" AP(4)A dose-response curve was to the left of that of ATP, and maximum response was greater than that produced by ATP."( Contractile activity of ATP and diadenosine tetraphosphate on urinary bladder in the rat: role of A1- and P2X-purinoceptors and nitric oxide.
Al-Hrasen, MN; El-Hadiyah, TM; Khattab, MM, 2007
)
0.34
" Gabapentin and R-PIA were administered to obtain the dose-response curve and the 50% effective dose (ED(50))."( The interaction of gabapentin and N6-(2-phenylisopropyl)-adenosine R-(-)isomer (R-PIA) on mechanical allodynia in rats with a spinal nerve ligation.
Jun, IG; Park, JY, 2008
)
0.35
"To compare the impact of caffeine on PPI expression in C57BL/6 mice by two dose-response experiments differing in terms of chronicity, regimen, and route of administration."( Sensorimotor gating is disrupted by acute but not chronic systemic exposure to caffeine in mice.
Dubroqua, S; Singer, P; Yee, BK, 2014
)
0.4
" Two separate dose-response studies tested the acute effect of the selective A₁R antagonist, 1,3 dipropyl-8 cyclopentyl xanthine (DPCPX), and the selective A₂AR antagonist, 5-amino-7-(2-phenylethyl)-2-(2-furyl)-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c] (SCH 58261) (0."( Sensorimotor gating is disrupted by acute but not chronic systemic exposure to caffeine in mice.
Dubroqua, S; Singer, P; Yee, BK, 2014
)
0.4
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
adenosine A1 receptor antagonistAn antagonist at the A1 receptor.
EC 3.1.4.* (phosphoric diester hydrolase) inhibitorAn EC 3.1.* (ester hydrolase) inhibitor that interferes with the action of a phosphoric diester hydrolase (EC 3.1.4.*).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
oxopurine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Purinergic signaling053

Protein Targets (32)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
thioredoxin reductaseRattus norvegicus (Norway rat)Potency37.68580.100020.879379.4328AID588453
ATAD5 protein, partialHomo sapiens (human)Potency18.34890.004110.890331.5287AID493107
TDP1 proteinHomo sapiens (human)Potency3.66260.000811.382244.6684AID686978
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency10.00000.00137.762544.6684AID914; AID915
thyroid stimulating hormone receptorHomo sapiens (human)Potency6.30960.001318.074339.8107AID926; AID938
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency33.49150.001530.607315,848.9004AID1224819; AID1224820
67.9K proteinVaccinia virusPotency10.00000.00018.4406100.0000AID720580
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency0.01580.035520.977089.1251AID504332
peripheral myelin protein 22 isoform 1Homo sapiens (human)Potency84.921423.934123.934123.9341AID1967
chromobox protein homolog 1Homo sapiens (human)Potency79.43280.006026.168889.1251AID540317
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency23.10930.00419.984825.9290AID504444
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency0.44670.050127.073689.1251AID588590
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency35.48130.00798.23321,122.0200AID2551
gemininHomo sapiens (human)Potency18.22260.004611.374133.4983AID463097; AID504364
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency22.38720.00106.000935.4813AID943
lamin isoform A-delta10Homo sapiens (human)Potency26.63210.891312.067628.1838AID1459; AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
5-hydroxytryptamine receptor 1AHomo sapiens (human)Ki1.02950.00010.532610.0000AID34871; AID34889
Adenosine receptor A3Homo sapiens (human)Ki2.08390.00000.930610.0000AID1289971; AID1416788; AID1482178; AID1608205; AID1658920; AID1744269; AID1798061; AID1802053; AID1822221; AID238978; AID239212; AID256820; AID256850; AID266823; AID297166; AID302711; AID320642; AID324665; AID32762; AID34120; AID34578; AID34868; AID34870; AID34871; AID34889; AID361544; AID408425; AID414670; AID418503; AID462292; AID478645; AID537180; AID661341; AID763040; AID763041; AID775949
Adenosine receptor A1Rattus norvegicus (Norway rat)IC50 (µMol)0.00510.00020.552110.0000AID31421; AID336464
Adenosine receptor A1Rattus norvegicus (Norway rat)Ki0.00080.00011.20929.9700AID1248361; AID1248362; AID239176; AID30339; AID30341; AID31882; AID31883; AID32016; AID32033; AID32168; AID32177; AID32192; AID32194; AID32481; AID32485; AID32487; AID32491; AID32493; AID32494; AID32496; AID32500; AID32508; AID32514; AID383540
Adenosine receptor A1Bos taurus (cattle)Ki0.00050.00000.71316.0000AID256809; AID266829; AID31982; AID31983; AID31984; AID31994; AID31999; AID414676
Adenosine receptor A3Rattus norvegicus (Norway rat)IC50 (µMol)0.00380.00070.03740.0957AID1375318
Adenosine receptor A3Rattus norvegicus (Norway rat)Ki3.29500.00030.91969.0000AID33486; AID408425
Adenosine receptor A2aHomo sapiens (human)IC50 (µMol)0.20330.00071.559410.0000AID1608214; AID33618; AID33620
Adenosine receptor A2aHomo sapiens (human)Ki15,444.20090.00001.06099.7920AID1174137; AID1289967; AID1482176; AID1608203; AID1618060; AID1658916; AID1744262; AID1798052; AID1798054; AID1798061; AID1802052; AID1822217; AID238923; AID254542; AID256818; AID256849; AID266827; AID266829; AID297170; AID302710; AID30502; AID30625; AID30790; AID30797; AID320641; AID324663; AID33613; AID33615; AID33623; AID33734; AID33926; AID34237; AID34238; AID34239; AID361540; AID396976; AID408429; AID414674; AID418501; AID478644; AID537176; AID661339; AID763042; AID763043; AID775950; AID92373
Adenosine receptor A2bHomo sapiens (human)IC50 (µMol)0.02340.00050.30231.5000AID1375318; AID1608209
Adenosine receptor A2bHomo sapiens (human)Ki0.58570.00021.635210.0000AID1289969; AID1482177; AID1658918; AID1744267; AID1822219; AID239265; AID266271; AID30502; AID30625; AID30790; AID30797; AID33176; AID33475; AID33734; AID418502; AID494495; AID537178; AID92373
Adenosine receptor A2bRattus norvegicus (Norway rat)Ki0.33520.00061.353610.0000AID30797; AID30810; AID30811; AID33432; AID33563; AID33565; AID33576; AID33610; AID33728; AID33734; AID33740
Adenosine receptor A1Homo sapiens (human)IC50 (µMol)0.00830.00020.68187.7010AID1285608; AID1336300; AID30303; AID30306; AID340231; AID346395; AID566237; AID751905; AID752265
Adenosine receptor A1Homo sapiens (human)Ki20,737.63760.00020.931610.0000AID1174135; AID1289965; AID1482175; AID1608201; AID1618058; AID1658914; AID1744264; AID1798052; AID1798054; AID1798061; AID1802051; AID1819979; AID1822209; AID1880702; AID238847; AID254536; AID256816; AID256848; AID266272; AID266825; AID275291; AID297168; AID302709; AID30438; AID30442; AID30444; AID30447; AID30450; AID30457; AID30772; AID312874; AID320640; AID324661; AID346395; AID361538; AID396975; AID408427; AID414672; AID418500; AID437483; AID478643; AID494497; AID537174; AID661338; AID751905; AID775951
Adenosine receptor A2aRattus norvegicus (Norway rat)Ki0.34680.00021.494010.0000AID1248361; AID1798054; AID239211; AID30797; AID30810; AID30811; AID32865; AID33008; AID33432; AID33563; AID33565; AID33576; AID33728; AID33734; AID33740; AID33934; AID33940; AID383542
Mu-type opioid receptorHomo sapiens (human)Ki100.00000.00000.419710.0000AID437485
Adenosine receptor A1Cavia porcellus (domestic guinea pig)Ki0.00600.00030.45466.9000AID1692735; AID32162; AID32163; AID32164; AID32168; AID32289; AID32292; AID32294
Sigma non-opioid intracellular receptor 1Cavia porcellus (domestic guinea pig)Ki0.26000.00000.338510.0000AID256818
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Adenosine receptor A1Rattus norvegicus (Norway rat)Kd0.00580.00130.56301.9498AID30336
Adenosine receptor A2aHomo sapiens (human)Kd0.07090.00020.47319.6000AID1342781; AID1342783; AID1802052
Adenosine receptor A2bHomo sapiens (human)EC50 (µMol)1.00000.00030.946110.0000AID1608207
Adenosine receptor A1Homo sapiens (human)EC50 (µMol)0.46740.00010.99169.8000AID1608211; AID1880699
Adenosine receptor A1Homo sapiens (human)Kd0.00310.00020.46215.9000AID1342822; AID1802051; AID31102
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Adenosine receptor A1Rattus norvegicus (Norway rat)Kb0.00020.00021.73678.7000AID31694
Adenosine receptor A2aHomo sapiens (human)ED5010.00000.30000.30000.3000AID224014
Adenosine receptor A2bRattus norvegicus (Norway rat)Kb0.25000.25002.14755.4000AID156510
Adenosine receptor A2bRattus norvegicus (Norway rat)Ratio0.34000.00330.82929.6000AID33746
Adenosine receptor A2aRattus norvegicus (Norway rat)Kb0.25000.00071.84855.4000AID156510
Adenosine receptor A2aRattus norvegicus (Norway rat)Ratio0.34000.00330.82309.6000AID33746
Vasopressin V2 receptorSus scrofa (pig)Kb0.14000.14000.14000.1400AID34304
Adenylate cyclase type 5Rattus norvegicus (Norway rat)Kb0.00050.00050.00050.0005AID34161
Adenylate cyclase type 1Homo sapiens (human)Kb0.10450.06900.10450.1400AID220594; AID34304
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (142)

Processvia Protein(s)Taxonomy
behavioral fear response5-hydroxytryptamine receptor 1AHomo sapiens (human)
G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
gamma-aminobutyric acid signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of serotonin secretion5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of vasoconstriction5-hydroxytryptamine receptor 1AHomo sapiens (human)
exploration behavior5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of dopamine metabolic process5-hydroxytryptamine receptor 1AHomo sapiens (human)
serotonin metabolic process5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of hormone secretion5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of behavior5-hydroxytryptamine receptor 1AHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 1AHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 1AHomo sapiens (human)
inflammatory responseAdenosine receptor A3Homo sapiens (human)
signal transductionAdenosine receptor A3Homo sapiens (human)
activation of adenylate cyclase activityAdenosine receptor A3Homo sapiens (human)
regulation of heart contractionAdenosine receptor A3Homo sapiens (human)
negative regulation of cell population proliferationAdenosine receptor A3Homo sapiens (human)
response to woundingAdenosine receptor A3Homo sapiens (human)
regulation of norepinephrine secretionAdenosine receptor A3Homo sapiens (human)
negative regulation of cell migrationAdenosine receptor A3Homo sapiens (human)
negative regulation of NF-kappaB transcription factor activityAdenosine receptor A3Homo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAdenosine receptor A3Homo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A3Homo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A1Bos taurus (cattle)
response to purine-containing compoundAdenosine receptor A1Bos taurus (cattle)
synaptic transmission, dopaminergicAdenosine receptor A2aHomo sapiens (human)
response to amphetamineAdenosine receptor A2aHomo sapiens (human)
regulation of DNA-templated transcriptionAdenosine receptor A2aHomo sapiens (human)
phagocytosisAdenosine receptor A2aHomo sapiens (human)
apoptotic processAdenosine receptor A2aHomo sapiens (human)
inflammatory responseAdenosine receptor A2aHomo sapiens (human)
cellular defense responseAdenosine receptor A2aHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
cell-cell signalingAdenosine receptor A2aHomo sapiens (human)
synaptic transmission, cholinergicAdenosine receptor A2aHomo sapiens (human)
central nervous system developmentAdenosine receptor A2aHomo sapiens (human)
blood coagulationAdenosine receptor A2aHomo sapiens (human)
sensory perceptionAdenosine receptor A2aHomo sapiens (human)
locomotory behaviorAdenosine receptor A2aHomo sapiens (human)
blood circulationAdenosine receptor A2aHomo sapiens (human)
negative regulation of cell population proliferationAdenosine receptor A2aHomo sapiens (human)
response to xenobiotic stimulusAdenosine receptor A2aHomo sapiens (human)
response to inorganic substanceAdenosine receptor A2aHomo sapiens (human)
positive regulation of glutamate secretionAdenosine receptor A2aHomo sapiens (human)
positive regulation of acetylcholine secretion, neurotransmissionAdenosine receptor A2aHomo sapiens (human)
regulation of norepinephrine secretionAdenosine receptor A2aHomo sapiens (human)
response to purine-containing compoundAdenosine receptor A2aHomo sapiens (human)
response to caffeineAdenosine receptor A2aHomo sapiens (human)
positive regulation of synaptic transmission, GABAergicAdenosine receptor A2aHomo sapiens (human)
synaptic transmission, glutamatergicAdenosine receptor A2aHomo sapiens (human)
positive regulation of urine volumeAdenosine receptor A2aHomo sapiens (human)
vasodilationAdenosine receptor A2aHomo sapiens (human)
eating behaviorAdenosine receptor A2aHomo sapiens (human)
negative regulation of vascular permeabilityAdenosine receptor A2aHomo sapiens (human)
negative regulation of neuron apoptotic processAdenosine receptor A2aHomo sapiens (human)
positive regulation of circadian sleep/wake cycle, sleepAdenosine receptor A2aHomo sapiens (human)
negative regulation of alpha-beta T cell activationAdenosine receptor A2aHomo sapiens (human)
astrocyte activationAdenosine receptor A2aHomo sapiens (human)
neuron projection morphogenesisAdenosine receptor A2aHomo sapiens (human)
positive regulation of protein secretionAdenosine receptor A2aHomo sapiens (human)
negative regulation of inflammatory responseAdenosine receptor A2aHomo sapiens (human)
regulation of mitochondrial membrane potentialAdenosine receptor A2aHomo sapiens (human)
membrane depolarizationAdenosine receptor A2aHomo sapiens (human)
regulation of calcium ion transportAdenosine receptor A2aHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicAdenosine receptor A2aHomo sapiens (human)
excitatory postsynaptic potentialAdenosine receptor A2aHomo sapiens (human)
inhibitory postsynaptic potentialAdenosine receptor A2aHomo sapiens (human)
prepulse inhibitionAdenosine receptor A2aHomo sapiens (human)
apoptotic signaling pathwayAdenosine receptor A2aHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAdenosine receptor A2aHomo sapiens (human)
positive regulation of long-term synaptic potentiationAdenosine receptor A2aHomo sapiens (human)
positive regulation of apoptotic signaling pathwayAdenosine receptor A2aHomo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A2bHomo sapiens (human)
positive regulation of chronic inflammatory response to non-antigenic stimulusAdenosine receptor A2bHomo sapiens (human)
G protein-coupled receptor signaling pathwayAdenosine receptor A2bHomo sapiens (human)
activation of adenylate cyclase activityAdenosine receptor A2bHomo sapiens (human)
positive regulation of vascular endothelial growth factor productionAdenosine receptor A2bHomo sapiens (human)
positive regulation of cGMP-mediated signalingAdenosine receptor A2bHomo sapiens (human)
cGMP-mediated signalingAdenosine receptor A2bHomo sapiens (human)
positive regulation of chemokine productionAdenosine receptor A2bHomo sapiens (human)
positive regulation of interleukin-6 productionAdenosine receptor A2bHomo sapiens (human)
mast cell degranulationAdenosine receptor A2bHomo sapiens (human)
positive regulation of mast cell degranulationAdenosine receptor A2bHomo sapiens (human)
relaxation of vascular associated smooth muscleAdenosine receptor A2bHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAdenosine receptor A2bHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAdenosine receptor A2bHomo sapiens (human)
vasodilationAdenosine receptor A2bHomo sapiens (human)
temperature homeostasisAdenosine receptor A1Homo sapiens (human)
response to hypoxiaAdenosine receptor A1Homo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A1Homo sapiens (human)
regulation of respiratory gaseous exchange by nervous system processAdenosine receptor A1Homo sapiens (human)
negative regulation of acute inflammatory responseAdenosine receptor A1Homo sapiens (human)
negative regulation of leukocyte migrationAdenosine receptor A1Homo sapiens (human)
positive regulation of peptide secretionAdenosine receptor A1Homo sapiens (human)
positive regulation of systemic arterial blood pressureAdenosine receptor A1Homo sapiens (human)
negative regulation of systemic arterial blood pressureAdenosine receptor A1Homo sapiens (human)
regulation of glomerular filtrationAdenosine receptor A1Homo sapiens (human)
protein targeting to membraneAdenosine receptor A1Homo sapiens (human)
phagocytosisAdenosine receptor A1Homo sapiens (human)
inflammatory responseAdenosine receptor A1Homo sapiens (human)
signal transductionAdenosine receptor A1Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayAdenosine receptor A1Homo sapiens (human)
cell-cell signalingAdenosine receptor A1Homo sapiens (human)
nervous system developmentAdenosine receptor A1Homo sapiens (human)
negative regulation of cell population proliferationAdenosine receptor A1Homo sapiens (human)
response to inorganic substanceAdenosine receptor A1Homo sapiens (human)
negative regulation of glutamate secretionAdenosine receptor A1Homo sapiens (human)
response to purine-containing compoundAdenosine receptor A1Homo sapiens (human)
lipid catabolic processAdenosine receptor A1Homo sapiens (human)
negative regulation of synaptic transmission, GABAergicAdenosine receptor A1Homo sapiens (human)
positive regulation of nucleoside transportAdenosine receptor A1Homo sapiens (human)
negative regulation of neurotrophin productionAdenosine receptor A1Homo sapiens (human)
positive regulation of protein dephosphorylationAdenosine receptor A1Homo sapiens (human)
vasodilationAdenosine receptor A1Homo sapiens (human)
negative regulation of circadian sleep/wake cycle, non-REM sleepAdenosine receptor A1Homo sapiens (human)
negative regulation of apoptotic processAdenosine receptor A1Homo sapiens (human)
positive regulation of potassium ion transportAdenosine receptor A1Homo sapiens (human)
positive regulation of MAPK cascadeAdenosine receptor A1Homo sapiens (human)
negative regulation of hormone secretionAdenosine receptor A1Homo sapiens (human)
cognitionAdenosine receptor A1Homo sapiens (human)
leukocyte migrationAdenosine receptor A1Homo sapiens (human)
detection of temperature stimulus involved in sensory perception of painAdenosine receptor A1Homo sapiens (human)
negative regulation of lipid catabolic processAdenosine receptor A1Homo sapiens (human)
positive regulation of lipid catabolic processAdenosine receptor A1Homo sapiens (human)
regulation of sensory perception of painAdenosine receptor A1Homo sapiens (human)
negative regulation of synaptic transmission, glutamatergicAdenosine receptor A1Homo sapiens (human)
fatty acid homeostasisAdenosine receptor A1Homo sapiens (human)
excitatory postsynaptic potentialAdenosine receptor A1Homo sapiens (human)
long-term synaptic depressionAdenosine receptor A1Homo sapiens (human)
mucus secretionAdenosine receptor A1Homo sapiens (human)
negative regulation of mucus secretionAdenosine receptor A1Homo sapiens (human)
triglyceride homeostasisAdenosine receptor A1Homo sapiens (human)
regulation of cardiac muscle cell contractionAdenosine receptor A1Homo sapiens (human)
apoptotic signaling pathwayAdenosine receptor A1Homo sapiens (human)
regulation of presynaptic cytosolic calcium ion concentrationAdenosine receptor A1Homo sapiens (human)
negative regulation of long-term synaptic potentiationAdenosine receptor A1Homo sapiens (human)
negative regulation of long-term synaptic depressionAdenosine receptor A1Homo sapiens (human)
G protein-coupled receptor signaling pathwayAdenosine receptor A1Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMu-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
sensory perceptionMu-type opioid receptorHomo sapiens (human)
negative regulation of cell population proliferationMu-type opioid receptorHomo sapiens (human)
sensory perception of painMu-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
behavioral response to ethanolMu-type opioid receptorHomo sapiens (human)
positive regulation of neurogenesisMu-type opioid receptorHomo sapiens (human)
negative regulation of Wnt protein secretionMu-type opioid receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeMu-type opioid receptorHomo sapiens (human)
calcium ion transmembrane transportMu-type opioid receptorHomo sapiens (human)
cellular response to morphineMu-type opioid receptorHomo sapiens (human)
regulation of cellular response to stressMu-type opioid receptorHomo sapiens (human)
regulation of NMDA receptor activityMu-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayMu-type opioid receptorHomo sapiens (human)
cAMP biosynthetic processAdenylate cyclase type 1Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAdenylate cyclase type 1Homo sapiens (human)
axonogenesisAdenylate cyclase type 1Homo sapiens (human)
long-term memoryAdenylate cyclase type 1Homo sapiens (human)
circadian rhythmAdenylate cyclase type 1Homo sapiens (human)
response to xenobiotic stimulusAdenylate cyclase type 1Homo sapiens (human)
cAMP-mediated signalingAdenylate cyclase type 1Homo sapiens (human)
positive regulation of CREB transcription factor activityAdenylate cyclase type 1Homo sapiens (human)
regulation of circadian rhythmAdenylate cyclase type 1Homo sapiens (human)
cellular response to calcium ionAdenylate cyclase type 1Homo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAdenylate cyclase type 1Homo sapiens (human)
neuroinflammatory responseAdenylate cyclase type 1Homo sapiens (human)
positive regulation of long-term synaptic potentiationAdenylate cyclase type 1Homo sapiens (human)
cellular response to forskolinAdenylate cyclase type 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (30)

Processvia Protein(s)Taxonomy
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 1AHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 1AHomo sapiens (human)
receptor-receptor interaction5-hydroxytryptamine receptor 1AHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 1AHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 1AHomo sapiens (human)
G protein-coupled adenosine receptor activityAdenosine receptor A3Homo sapiens (human)
G protein-coupled adenosine receptor activityAdenosine receptor A2aHomo sapiens (human)
protein bindingAdenosine receptor A2aHomo sapiens (human)
calmodulin bindingAdenosine receptor A2aHomo sapiens (human)
lipid bindingAdenosine receptor A2aHomo sapiens (human)
enzyme bindingAdenosine receptor A2aHomo sapiens (human)
type 5 metabotropic glutamate receptor bindingAdenosine receptor A2aHomo sapiens (human)
identical protein bindingAdenosine receptor A2aHomo sapiens (human)
protein-containing complex bindingAdenosine receptor A2aHomo sapiens (human)
alpha-actinin bindingAdenosine receptor A2aHomo sapiens (human)
G protein-coupled adenosine receptor activityAdenosine receptor A2bHomo sapiens (human)
protein bindingAdenosine receptor A2bHomo sapiens (human)
G protein-coupled receptor activityAdenosine receptor A2bHomo sapiens (human)
G protein-coupled receptor bindingAdenosine receptor A1Homo sapiens (human)
purine nucleoside bindingAdenosine receptor A1Homo sapiens (human)
protein bindingAdenosine receptor A1Homo sapiens (human)
heat shock protein bindingAdenosine receptor A1Homo sapiens (human)
G-protein beta/gamma-subunit complex bindingAdenosine receptor A1Homo sapiens (human)
heterotrimeric G-protein bindingAdenosine receptor A1Homo sapiens (human)
protein heterodimerization activityAdenosine receptor A1Homo sapiens (human)
G protein-coupled adenosine receptor activityAdenosine receptor A1Homo sapiens (human)
G protein-coupled adenosine receptor activityAdenosine receptor A2aRattus norvegicus (Norway rat)
G-protein alpha-subunit bindingMu-type opioid receptorHomo sapiens (human)
G protein-coupled receptor activityMu-type opioid receptorHomo sapiens (human)
beta-endorphin receptor activityMu-type opioid receptorHomo sapiens (human)
voltage-gated calcium channel activityMu-type opioid receptorHomo sapiens (human)
protein bindingMu-type opioid receptorHomo sapiens (human)
morphine receptor activityMu-type opioid receptorHomo sapiens (human)
G-protein beta-subunit bindingMu-type opioid receptorHomo sapiens (human)
neuropeptide bindingMu-type opioid receptorHomo sapiens (human)
calmodulin bindingAdenylate cyclase type 1Homo sapiens (human)
ATP bindingAdenylate cyclase type 1Homo sapiens (human)
calcium- and calmodulin-responsive adenylate cyclase activityAdenylate cyclase type 1Homo sapiens (human)
metal ion bindingAdenylate cyclase type 1Homo sapiens (human)
adenylate cyclase activityAdenylate cyclase type 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (30)

Processvia Protein(s)Taxonomy
plasma membrane5-hydroxytryptamine receptor 1AHomo sapiens (human)
synapse5-hydroxytryptamine receptor 1AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1AHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 1AHomo sapiens (human)
plasma membraneAdenosine receptor A3Homo sapiens (human)
presynaptic membraneAdenosine receptor A3Homo sapiens (human)
Schaffer collateral - CA1 synapseAdenosine receptor A3Homo sapiens (human)
dendriteAdenosine receptor A3Homo sapiens (human)
plasma membraneAdenosine receptor A3Homo sapiens (human)
synapseAdenosine receptor A3Homo sapiens (human)
plasma membraneAdenosine receptor A2aHomo sapiens (human)
intermediate filamentAdenosine receptor A2aHomo sapiens (human)
plasma membraneAdenosine receptor A2aHomo sapiens (human)
membraneAdenosine receptor A2aHomo sapiens (human)
dendriteAdenosine receptor A2aHomo sapiens (human)
axolemmaAdenosine receptor A2aHomo sapiens (human)
asymmetric synapseAdenosine receptor A2aHomo sapiens (human)
presynaptic membraneAdenosine receptor A2aHomo sapiens (human)
neuronal cell bodyAdenosine receptor A2aHomo sapiens (human)
postsynaptic membraneAdenosine receptor A2aHomo sapiens (human)
presynaptic active zoneAdenosine receptor A2aHomo sapiens (human)
glutamatergic synapseAdenosine receptor A2aHomo sapiens (human)
plasma membraneAdenosine receptor A2bHomo sapiens (human)
Schaffer collateral - CA1 synapseAdenosine receptor A2bHomo sapiens (human)
presynapseAdenosine receptor A2bHomo sapiens (human)
glutamatergic synapseAdenosine receptor A2bHomo sapiens (human)
plasma membraneAdenosine receptor A2bHomo sapiens (human)
plasma membraneAdenosine receptor A1Homo sapiens (human)
plasma membraneAdenosine receptor A1Homo sapiens (human)
basolateral plasma membraneAdenosine receptor A1Homo sapiens (human)
axolemmaAdenosine receptor A1Homo sapiens (human)
asymmetric synapseAdenosine receptor A1Homo sapiens (human)
presynaptic membraneAdenosine receptor A1Homo sapiens (human)
neuronal cell bodyAdenosine receptor A1Homo sapiens (human)
terminal boutonAdenosine receptor A1Homo sapiens (human)
dendritic spineAdenosine receptor A1Homo sapiens (human)
calyx of HeldAdenosine receptor A1Homo sapiens (human)
postsynaptic membraneAdenosine receptor A1Homo sapiens (human)
presynaptic active zoneAdenosine receptor A1Homo sapiens (human)
synapseAdenosine receptor A1Homo sapiens (human)
dendriteAdenosine receptor A1Homo sapiens (human)
Golgi membraneAdenosine receptor A2aRattus norvegicus (Norway rat)
endosomeMu-type opioid receptorHomo sapiens (human)
endoplasmic reticulumMu-type opioid receptorHomo sapiens (human)
Golgi apparatusMu-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorHomo sapiens (human)
axonMu-type opioid receptorHomo sapiens (human)
dendriteMu-type opioid receptorHomo sapiens (human)
perikaryonMu-type opioid receptorHomo sapiens (human)
synapseMu-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorHomo sapiens (human)
neuron projectionMu-type opioid receptorHomo sapiens (human)
cytoplasmAdenylate cyclase type 1Homo sapiens (human)
plasma membraneAdenylate cyclase type 1Homo sapiens (human)
membrane raftAdenylate cyclase type 1Homo sapiens (human)
extracellular exosomeAdenylate cyclase type 1Homo sapiens (human)
Schaffer collateral - CA1 synapseAdenylate cyclase type 1Homo sapiens (human)
hippocampal mossy fiber to CA3 synapseAdenylate cyclase type 1Homo sapiens (human)
presynapseAdenylate cyclase type 1Homo sapiens (human)
postsynaptic density membraneAdenylate cyclase type 1Homo sapiens (human)
glutamatergic synapseAdenylate cyclase type 1Homo sapiens (human)
plasma membraneAdenylate cyclase type 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (461)

Assay IDTitleYearJournalArticle
AID30442Binding affinity against adenosine A1 receptor in human cortical membranes using [3H]CHA as radioligand2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Study on affinity profile toward native human and bovine adenosine receptors of a series of 1,8-naphthyridine derivatives.
AID408429Displacement of [125I]NECA from human cloned adenosine A2A receptor expressed in CHO cells2008Bioorganic & medicinal chemistry, Jun-01, Volume: 16, Issue:11
Synthesis, ligand-receptor modeling studies and pharmacological evaluation of novel 4-modified-2-aryl-1,2,4-triazolo[4,3-a]quinoxalin-1-one derivatives as potent and selective human A3 adenosine receptor antagonists.
AID32493Inhibition of N6-[3H]cyclohexyladenosine binding to adenosine A1 receptor from rat cortical membranes1992Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12
(E)-1,3-dialkyl-7-methyl-8-(3,4,5-trimethoxystyryl)xanthines: potent and selective adenosine A2 antagonists.
AID189932Ratio of urinary excretion value (urinary volume) in treated rats to that in control rats, at a peroral dose of 0.1 mg/Kg1992Journal of medicinal chemistry, Aug-07, Volume: 35, Issue:16
Adenosine A1 antagonists. 2. Structure-activity relationships on diuretic activities and protective effects against acute renal failure.
AID33586Binding affinity towards adenosine A2 receptor in rat striatal membranes using N-[3H]-ethyladenosin-5''-uronamide as radioligand1992Journal of medicinal chemistry, Aug-07, Volume: 35, Issue:16
Adenosine A1 antagonists. 2. Structure-activity relationships on diuretic activities and protective effects against acute renal failure.
AID31984Binding affinity at bovine Adenosine A1 receptor.2002Journal of medicinal chemistry, Oct-24, Volume: 45, Issue:22
Synthesis, molecular modeling studies, and pharmacological activity of selective A(1) receptor antagonists.
AID256848Displacement of [3H]DPCPX from human adenosine A1 receptor expressed in CHO cells2005Journal of medicinal chemistry, Dec-29, Volume: 48, Issue:26
2-(Benzimidazol-2-yl)quinoxalines: a novel class of selective antagonists at human A(1) and A(3) adenosine receptors designed by 3D database searching.
AID266271Displacement of [3H]ZM241385 from human adenosine A2b receptor expressed in HEK cells2006Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12
Novel 1,3-disubstituted 8-(1-benzyl-1H-pyrazol-4-yl) xanthines: high affinity and selective A2B adenosine receptor antagonists.
AID1248370Displacement of [3H]-NECA from Adenosine A2A receptor in rat striatal membranes2015Bioorganic & medicinal chemistry, Oct-15, Volume: 23, Issue:20
1,3,7-Triethyl-substituted xanthines--possess nanomolar affinity for the adenosine A1 receptor.
AID449705NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID30450Binding affinity for human Adenosine A1 receptor2004Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3
Synthesis and biological evaluation of 2,3,5-substituted [1,2,4]thiadiazoles as allosteric modulators of adenosine receptors.
AID752265Binding affinity to human adenosine A1 receptor by radioligand displacement assay2013Bioorganic & medicinal chemistry, May-15, Volume: 21, Issue:10
Synthesis and biological evaluation of 2-(5-methyl-4-phenyl-2-oxopyrrolidin-1-yl)-acetamide stereoisomers as novel positive allosteric modulators of sigma-1 receptor.
AID229656Selectivity ratio of the compound( A2A/A2B)2002Journal of medicinal chemistry, Mar-28, Volume: 45, Issue:7
1,8-disubstituted xanthine derivatives: synthesis of potent A2B-selective adenosine receptor antagonists.
AID34578Binding affinity against human adenosine A3 receptor expressed in CHO cells by [125I]AB-MECA displacement.2004Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14
1,2,4-triazolo[4,3-a]quinoxalin-1-one moiety as an attractive scaffold to develop new potent and selective human A3 adenosine receptor antagonists: synthesis, pharmacological, and ligand-receptor modeling studies.
AID32762Inhibition of [3H]PSB-11 binding to human Adenosine A3 receptor2002Journal of medicinal chemistry, Mar-28, Volume: 45, Issue:7
1,8-disubstituted xanthine derivatives: synthesis of potent A2B-selective adenosine receptor antagonists.
AID408425Displacement of [125I]AB-MECA from human cloned adenosine A3 receptor expressed in CHO cells2008Bioorganic & medicinal chemistry, Jun-01, Volume: 16, Issue:11
Synthesis, ligand-receptor modeling studies and pharmacological evaluation of novel 4-modified-2-aryl-1,2,4-triazolo[4,3-a]quinoxalin-1-one derivatives as potent and selective human A3 adenosine receptor antagonists.
AID32192Binding affinity towards adenosine A1 receptor in rat cortical membranes using N6-[3H]cyclohexyladenosine as radioligand1992Journal of medicinal chemistry, Aug-07, Volume: 35, Issue:16
Adenosine A1 antagonists. 2. Structure-activity relationships on diuretic activities and protective effects against acute renal failure.
AID1880711Cytotoxicity against human PC-3 cells assessed as cell viability incubated for 72 to 96 hrs by MTT assay
AID256820Displacement of [125I]AB-MECA from human adenosine A3 receptor expressed in CHO cells2005Journal of medicinal chemistry, Dec-15, Volume: 48, Issue:25
1,2,4-Triazolo[1,5-a]quinoxaline as a versatile tool for the design of selective human A3 adenosine receptor antagonists: synthesis, biological evaluation, and molecular modeling studies of 2-(hetero)aryl- and 2-carboxy-substituted derivatives.
AID312874Displacement of [3H]DPCPX from human recombinant adenosine A1 receptor expressed in HEK293 cells2008Journal of medicinal chemistry, Feb-14, Volume: 51, Issue:3
Identification of novel, water-soluble, 2-amino-N-pyrimidin-4-yl acetamides as A2A receptor antagonists with in vivo efficacy.
AID30457Binding affinity towards human A1 receptor (hA1) was measured through displacement of [3H]-DPCPX using mammalian cell membranes1999Bioorganic & medicinal chemistry letters, Aug-16, Volume: 9, Issue:16
Selective A1-adenosine receptor antagonists identified using yeast Saccharomyces cerevisiae functional assays.
AID1744267Displacement of [3H]DPCPX from human adenosine A2B receptor expressed in HEK293 cell membranes incubated for 30 mins by scintillation counting method2021Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1
3,4-Dihydropyrimidin-2(1
AID1608207Agonist activity at human A2B expressed in CHO cells assessed as stimulation of cAMP production by alphascreen assay
AID33753Ratio of the binding affinities of A2 /A1 receptor1991Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
1,3,8-trisubstituted xanthines. Effects of substitution pattern upon adenosine receptor A1/A2 affinity.
AID252601Effect on forskolin-induced cAMP levels at human A1 adenosine receptor compared to CPA (full agonist, 100% inhibition) and DPCPX(full inverse agonist, 100% stimulation)2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
A series of ligands displaying a remarkable agonistic-antagonistic profile at the adenosine A1 receptor.
AID524790Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID31102pA2 against human brain adenosine A1 receptor1998Bioorganic & medicinal chemistry letters, Mar-17, Volume: 8, Issue:6
Diimidazo[1,2-c:4',5'-e]pyrimidines: adenosine agonist activity demonstrated by microphysiometry.
AID275284Reduction of PrPSC accumulation in ScN2a cells2007Journal of medicinal chemistry, Jan-11, Volume: 50, Issue:1
Structure-activity relationship study of prion inhibition by 2-aminopyridine-3,5-dicarbonitrile-based compounds: parallel synthesis, bioactivity, and in vitro pharmacokinetics.
AID32016Binding affinity of specific [3H]R-PIA binding to rat Adenosine A1 receptor in HEK293 cells2002Journal of medicinal chemistry, May-23, Volume: 45, Issue:11
Structure-activity relationships at human and rat A2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions.
AID192859Compound was evaluated for Urea Nitrogen concentration in glycerol injected rats treated with 1 mg/kg administered intraperitoneally1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
8-(Dicyclopropylmethyl)-1,3-dipropylxanthine: a potent and selective adenosine A1 antagonist with renal protective and diuretic activities.
AID462284Displacement of [3H]CCPA from adenosine A1 receptor in rat brain cortex membrane2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists.
AID408427Displacement of [125I]DPCPX from human cloned adenosine A1 receptor expressed in CHO cells2008Bioorganic & medicinal chemistry, Jun-01, Volume: 16, Issue:11
Synthesis, ligand-receptor modeling studies and pharmacological evaluation of novel 4-modified-2-aryl-1,2,4-triazolo[4,3-a]quinoxalin-1-one derivatives as potent and selective human A3 adenosine receptor antagonists.
AID108720Acquisition time in (R)-PIA) induced avoidance test (performed in mice) for antagonistic activity after peroral administration of 0.31 mg/kg (n=15)1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
Adenosine A1 antagonists. 3. Structure-activity relationships on amelioration against scopolamine- or N6-((R)-phenylisopropyl)adenosine-induced cognitive disturbance.
AID33008Inhibition of [3H]MSX-2 binding to rat adenosine A2A receptor2002Journal of medicinal chemistry, Mar-28, Volume: 45, Issue:7
1,8-disubstituted xanthine derivatives: synthesis of potent A2B-selective adenosine receptor antagonists.
AID33754Selectivity is defined as the ratio of Ki(A2 adenosine receptor) / Ki(A1 adenosine receptor)1992Journal of medicinal chemistry, Mar-06, Volume: 35, Issue:5
8-Polycycloalkyl-1,3-dipropylxanthines as potent and selective antagonists for A1-adenosine receptors.
AID191572Retention time in Scopolamine induced avoidance test (performed in rat) for antagonistic activity after peroral administration of 5 mg/kg1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
Adenosine A1 antagonists. 3. Structure-activity relationships on amelioration against scopolamine- or N6-((R)-phenylisopropyl)adenosine-induced cognitive disturbance.
AID297166Displacement of [125I]AB-MECA from human adenosine A3 receptor expressed in CHO cells2007Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17
New 2-arylpyrazolo[3,4-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluation, and ligand-receptor modeling studies.
AID30797Inhibition of the stimulation by 5'-(N-ethylcarbamoyl) adenosine of adenyl cyclase via adenosine A2 receptor in human platelet membranes.1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
Effects of 8-phenyl and 8-cycloalkyl substituents on the activity of mono-, di-, and trisubstituted alkylxanthines with substitution at the 1-, 3-, and 7-positions.
AID34868Displacement of [125I]AB-MECA from human adenosine A3 receptor expressed in CHO cells1998Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21
A novel class of adenosine A3 receptor ligands. 1. 3-(2-Pyridinyl)isoquinoline derivatives.
AID24458Compound administered at a dose of 6.25 mg/25 mL/kg orally to rats, urine collected for 6 hr and measured for Na+ excretion.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
8-(Dicyclopropylmethyl)-1,3-dipropylxanthine: a potent and selective adenosine A1 antagonist with renal protective and diuretic activities.
AID1822219Displacement of [3H]DPCPX from human A2BAR expressed in HEK293 cell membrane incubated for 30 mins by microbeta trilux scintillation counter analysis2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Optimization of 2-Amino-4,6-diarylpyrimidine-5-carbonitriles as Potent and Selective A
AID33475Inhibition of [3H]ZM-241385 binding to human adenosine A2B receptor2002Journal of medicinal chemistry, Mar-28, Volume: 45, Issue:7
1,8-disubstituted xanthine derivatives: synthesis of potent A2B-selective adenosine receptor antagonists.
AID33441Binding affinity against adenosine A2 receptor in rat striatum by the displacement of [3H]N-ethyladenosine-5''-uronamide(NECA).1991Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
1,3,8-trisubstituted xanthines. Effects of substitution pattern upon adenosine receptor A1/A2 affinity.
AID34237Binding affinity for HA-tagged mutant human Adenosine A2A receptor (H250N) using [3H]-CGS-21,680 as radioligand expressed in COS-7 cells1997Journal of medicinal chemistry, Aug-01, Volume: 40, Issue:16
Mutagenesis reveals structure-activity parallels between human A2A adenosine receptors and biogenic amine G protein-coupled receptors.
AID1608211Inverse agonist activity at human A1AR expressed in CHO cells assessed as increase in forskolin-stimulated cAMP production by alphascreen assay
AID32289Binding affinity towards adenosine A1 receptor using N6-[3H]cyclohexyladenosine in guinea pig forebrain membranes1992Journal of medicinal chemistry, Sep-18, Volume: 35, Issue:19
7,8-Dihydro-8-ethyl-2-(3-noradamantyl)-4-propyl-1H-imidazo[2,1-i]purin-5(4H)-one: a potent and water-soluble adenosine A1 antagonist.
AID191557Retention time in Scopolamine induced avoidance test (performed in rat) for antagonistic activity after peroral administration of 0.08 mg/kg (n=13) (P<0.01)1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
Adenosine A1 antagonists. 3. Structure-activity relationships on amelioration against scopolamine- or N6-((R)-phenylisopropyl)adenosine-induced cognitive disturbance.
AID408433Displacement of [3H]CGS21680 from adenosine A2A receptor in bovine brain membrane2008Bioorganic & medicinal chemistry, Jun-01, Volume: 16, Issue:11
Synthesis, ligand-receptor modeling studies and pharmacological evaluation of novel 4-modified-2-aryl-1,2,4-triazolo[4,3-a]quinoxalin-1-one derivatives as potent and selective human A3 adenosine receptor antagonists.
AID256850Displacement of [125I]AB-MECA from human adenosine A3 receptor expressed in CHO cells2005Journal of medicinal chemistry, Dec-29, Volume: 48, Issue:26
2-(Benzimidazol-2-yl)quinoxalines: a novel class of selective antagonists at human A(1) and A(3) adenosine receptors designed by 3D database searching.
AID1637877Displacement of [3H]DPCPX from adenosine A1 receptor in rat brain membranes by radioligand competition assay
AID34870Displacement of specific [125I]AB-MECA binding at human adenosine A3 receptor expressed in HEK 293 cells.1998Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21
A novel class of adenosine A3 receptor ligands. 1. 3-(2-Pyridinyl)isoquinoline derivatives.
AID256822Selectivity for human adenosine A3 receptor over human adenosine A1 receptor2005Journal of medicinal chemistry, Dec-15, Volume: 48, Issue:25
1,2,4-Triazolo[1,5-a]quinoxaline as a versatile tool for the design of selective human A3 adenosine receptor antagonists: synthesis, biological evaluation, and molecular modeling studies of 2-(hetero)aryl- and 2-carboxy-substituted derivatives.
AID220594KB for inhibition of adenylate cyclase stimulation in human platelet membranes1992Journal of medicinal chemistry, Mar-06, Volume: 35, Issue:5
8-Polycycloalkyl-1,3-dipropylxanthines as potent and selective antagonists for A1-adenosine receptors.
AID34889Displacement of [125I]AB-MECA from human adenosine A3 receptor expressed in CHO cells.2000Journal of medicinal chemistry, Aug-10, Volume: 43, Issue:16
Synthesis and structure-activity relationships of a new set of 2-arylpyrazolo[3,4-c]quinoline derivatives as adenosine receptor antagonists.
AID31993Displacement of [3H]CPX from Adenosine A1 receptor of bovine brain cerebral cortex membranes1998Journal of medicinal chemistry, Feb-12, Volume: 41, Issue:4
A1 adenosine receptor antagonists as ligands for positron emission tomography (PET) and single-photon emission tomography (SPET).
AID197762Urea nitrogen concentration measured after intraperitoneal administration of 1 mg/kg of compound to rats(vehicle 182.5+/-3.4)1992Journal of medicinal chemistry, Aug-07, Volume: 35, Issue:16
Adenosine A1 antagonists. 2. Structure-activity relationships on diuretic activities and protective effects against acute renal failure.
AID1658920Displacement [3H]NECA from adenosine A3 receptor in human HeLa cell membranes incubated for 180 mins by scintillation counting method2020Journal of medicinal chemistry, 07-23, Volume: 63, Issue:14
Nitrogen-Walk Approach to Explore Bioisosteric Replacements in a Series of Potent A
AID32162Binding affinity against adenosine A1 receptor from guinea pig forebrain membranes, using N6-[3H]cyclohexyladenosine as radioligand.1992Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12
(E)-1,3-dialkyl-7-methyl-8-(3,4,5-trimethoxystyryl)xanthines: potent and selective adenosine A2 antagonists.
AID9805Ratio of Ki for adenosine A2 and A1 receptor binding1992Journal of medicinal chemistry, Aug-07, Volume: 35, Issue:16
Adenosine A1 antagonists. 2. Structure-activity relationships on diuretic activities and protective effects against acute renal failure.
AID30503Ratio of binding to adenosine A2 and A1 receptors1992Journal of medicinal chemistry, Sep-18, Volume: 35, Issue:19
7,8-Dihydro-8-ethyl-2-(3-noradamantyl)-4-propyl-1H-imidazo[2,1-i]purin-5(4H)-one: a potent and water-soluble adenosine A1 antagonist.
AID266829Displacement of [3H]DPCPX from adenosine A1 receptor in bovine brain membranes2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
4-amido-2-aryl-1,2,4-triazolo[4,3-a]quinoxalin-1-ones as new potent and selective human A3 adenosine receptor antagonists. synthesis, pharmacological evaluation, and ligand-receptor modeling studies.
AID31982Binding affinity against adenosine A1 receptor in bovine brain membranes by [3H]CHA displacement.2004Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14
1,2,4-triazolo[4,3-a]quinoxalin-1-one moiety as an attractive scaffold to develop new potent and selective human A3 adenosine receptor antagonists: synthesis, pharmacological, and ligand-receptor modeling studies.
AID275291Inhibitory constant aganist human adenosine A1 receptor2007Journal of medicinal chemistry, Jan-11, Volume: 50, Issue:1
Structure-activity relationship study of prion inhibition by 2-aminopyridine-3,5-dicarbonitrile-based compounds: parallel synthesis, bioactivity, and in vitro pharmacokinetics.
AID188097Effect on urinary excretion potassium and sodium after oral administration of 25 mg/kg to rats(potassium and sodium excretion in control rat is 0.129+/-0.026)1992Journal of medicinal chemistry, Aug-07, Volume: 35, Issue:16
Adenosine A1 antagonists. 2. Structure-activity relationships on diuretic activities and protective effects against acute renal failure.
AID30811Inhibition of N-[3H]-ethyladenosin-5''-uronamide binding to adenosine A2 receptor from rat striatal membranes1992Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12
(E)-1,3-dialkyl-7-methyl-8-(3,4,5-trimethoxystyryl)xanthines: potent and selective adenosine A2 antagonists.
AID232493Selectivity as ratio of Ki against adenosine A2a and A1 receptor binding in guinea pig1997Journal of medicinal chemistry, Jun-06, Volume: 40, Issue:12
Synthesis and biological evaluation of the enantiomers of the potent and selective A1-adenosine antagonist 1,3-dipropyl-8-[2-(5,6-epoxynorbonyl)]-xanthine.
AID21767Solubility of the compound(10 mg) was measured in water(2.5 mL) at 20 degree celsius for 1 hr1992Journal of medicinal chemistry, Sep-18, Volume: 35, Issue:19
7,8-Dihydro-8-ethyl-2-(3-noradamantyl)-4-propyl-1H-imidazo[2,1-i]purin-5(4H)-one: a potent and water-soluble adenosine A1 antagonist.
AID32491Inhibition of 1 nM [3H]- N6-(phenylisopropyl) adenosine binding to Adenosine A1 receptor in rat cerebral cortical membranes1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
Effects of 8-phenyl and 8-cycloalkyl substituents on the activity of mono-, di-, and trisubstituted alkylxanthines with substitution at the 1-, 3-, and 7-positions.
AID92373Inhibition of 5'-(N-ethylcarbamoyl)adenosine-elicited stimulation of adenylate cyclase in human platelet membranes1988Journal of medicinal chemistry, Mar, Volume: 31, Issue:3
8-Aryl-and 8-cycloalkyl-1,3-dipropylxanthines: further potent and selective antagonists for A1-adenosine receptors.
AID191187Oral diuretic activity was measured after oral administration of 1.6 mg/kg to rats(control volume is 0.91+/-0.08)1992Journal of medicinal chemistry, Aug-07, Volume: 35, Issue:16
Adenosine A1 antagonists. 2. Structure-activity relationships on diuretic activities and protective effects against acute renal failure.
AID1416788Displacement of [3H]NECA from recombinant human adenosine A3 receptor expressed in CHO cell membranes measured after 180 mins2018MedChemComm, Jan-01, Volume: 9, Issue:1
Studies on enantioselectivity of chiral 4-acetylamino-6-alkyloxy-2-alkylthiopyrimidines acting as antagonists of the human A
AID1822209Displacement of [3H]DPCPX from human A1AR expressed in CHO cell membrane incubated for 60 mins by microbeta trilux scintillation counter analysis2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Optimization of 2-Amino-4,6-diarylpyrimidine-5-carbonitriles as Potent and Selective A
AID232494Selectivity as ratio of Ki against human adenosine A2a and A1 receptor binding1997Journal of medicinal chemistry, Jun-06, Volume: 40, Issue:12
Synthesis and biological evaluation of the enantiomers of the potent and selective A1-adenosine antagonist 1,3-dipropyl-8-[2-(5,6-epoxynorbonyl)]-xanthine.
AID197764Percent inhibition of serum creatinine by the compound given as ratio of Cr value in treated to vehicle treated ones after intraperitoneal administration of 1 mg/kg of compound to rats(vehicle 5.43+/-0.11)1992Journal of medicinal chemistry, Aug-07, Volume: 35, Issue:16
Adenosine A1 antagonists. 2. Structure-activity relationships on diuretic activities and protective effects against acute renal failure.
AID661341Displacement of [125I]AB-MECA from human A3 adenosine receptor expressed in CHO cell membrane2012Journal of medicinal chemistry, Feb-23, Volume: 55, Issue:4
3-aryl-[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-one: a novel template for the design of highly selective A₂B adenosine receptor antagonists.
AID30438Antagonist activity against adenosine A1 receptor in human platelets1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Structure-activity relationships of 8-cycloalkyl-1,3-dipropylxanthines as antagonists of adenosine receptors.
AID31875Binding affinity against adenosine A1 receptor using N6-[3H]-cyclohexyladenosinene in rat whole brain membranes1992Journal of medicinal chemistry, Mar-06, Volume: 35, Issue:5
8-Polycycloalkyl-1,3-dipropylxanthines as potent and selective antagonists for A1-adenosine receptors.
AID32643Relative affinities for rat Adenosine A1 and Adenosine A2B receptors2002Journal of medicinal chemistry, May-23, Volume: 45, Issue:11
Structure-activity relationships at human and rat A2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions.
AID478644Displacement of [3H]NECA from human adenosine A2A receptor expressed in CHO cells2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Novel N2-substituted pyrazolo[3,4-d]pyrimidine adenosine A3 receptor antagonists: inhibition of A3-mediated human glioblastoma cell proliferation.
AID33623Binding affinity towards human A2 receptor (hA2) was measured through displacement of [3H]-CGS-21,680 using yeast cell membranes1999Bioorganic & medicinal chemistry letters, Aug-16, Volume: 9, Issue:16
Selective A1-adenosine receptor antagonists identified using yeast Saccharomyces cerevisiae functional assays.
AID234645Selectivity as IC50 against adenosine A2A and adenosine A1 receptors1999Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14
Discovery of FR166124, a novel water-soluble pyrazolo-[1,5-a]pyridine adenosine A1 receptor antagonist.
AID661339Displacement of [3H]NECA from human A2A adenosine receptor expressed in CHO cell membrane2012Journal of medicinal chemistry, Feb-23, Volume: 55, Issue:4
3-aryl-[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-one: a novel template for the design of highly selective A₂B adenosine receptor antagonists.
AID229793Ratio of Ki for A2 and A1 adenosine receptors1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
Adenosine A1 antagonists. 3. Structure-activity relationships on amelioration against scopolamine- or N6-((R)-phenylisopropyl)adenosine-induced cognitive disturbance.
AID324665Displacement of [3H]AB-MECA from human adenosine A3 receptor expressed in HEK293 cells2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
A new generation of adenosine receptor antagonists: from di- to trisubstituted aminopyrimidines.
AID191545Retention time in Scopolamine induced avoidance test (performed in mice) for antagonistic activity after peroral administration of 1.25 mg/kg1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
Adenosine A1 antagonists. 3. Structure-activity relationships on amelioration against scopolamine- or N6-((R)-phenylisopropyl)adenosine-induced cognitive disturbance.
AID32496Inhibition of [3H]CCPA binding to rat adenosine A1 receptor2002Journal of medicinal chemistry, Mar-28, Volume: 45, Issue:7
1,8-disubstituted xanthine derivatives: synthesis of potent A2B-selective adenosine receptor antagonists.
AID191553Retention time in Scopolamine induced avoidance test (performed in rat) for antagonistic activity after peroral administration of 0.02 mg/kg (n=13)1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
Adenosine A1 antagonists. 3. Structure-activity relationships on amelioration against scopolamine- or N6-((R)-phenylisopropyl)adenosine-induced cognitive disturbance.
AID324661Displacement of [3H]DPCPX from human adenosine A1 receptor expressed in CHO cells2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
A new generation of adenosine receptor antagonists: from di- to trisubstituted aminopyrimidines.
AID1289969Displacement of [3H]DPCPX from human Adenosine A2B receptor expressed in HEK293 cells after 30 mins2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
Discovery of Potent and Highly Selective A2B Adenosine Receptor Antagonist Chemotypes.
AID32500Inhibition of binding of 1 nM [3H]N-6-(phenylisopropyl)adenosine to adenosine A1 receptor in rat cortical membranes1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
Sulfur-containing 1,3-dialkylxanthine derivatives as selective antagonists at A1-adenosine receptors.
AID462292Displacement of [3H]PSB-11 from human adenosine A3 receptor expressed in CHO cells2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists.
AID302709Displacement of [3H]DPCPX from human adenosine A1 receptor expressed in CHO cells2007Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23
5-amino-2-phenyl[1,2,3]triazolo[1,2-a][1,2,4]benzotriazin-1-one: a versatile scaffold to obtain potent and selective A3 adenosine receptor antagonists.
AID1267444Displacement of CA200645 from human adenosine A1 receptor expressed in CHO cells at 1 uM incubated for 1 hr by fluorescence analysis2015Journal of medicinal chemistry, Dec-24, Volume: 58, Issue:24
Fragment-Based Discovery of Subtype-Selective Adenosine Receptor Ligands from Homology Models.
AID197763Percent inhibition of Urea nitrogen by the compound given as ratio of UN value in treated to vehicle treated ones after intraperitoneal administration of 1 mg/kg of compound to rats(vehicle 182.5+/-3.4)1992Journal of medicinal chemistry, Aug-07, Volume: 35, Issue:16
Adenosine A1 antagonists. 2. Structure-activity relationships on diuretic activities and protective effects against acute renal failure.
AID481983Displacement of [3H]CCPA from adenosine A1 receptor in rat brain cortical membrane after 90 mins by scintillation counting2010European journal of medicinal chemistry, May, Volume: 45, Issue:5
Synthesis and theoretical studies on energetics of novel N- and O- perfluoroalkyl triazole tagged thienopyrimidines--their potential as adenosine receptor ligands.
AID31421Inhibitory activity against Adenosine A1 Receptor using [3H]CHA in rat cortical membranes1999Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14
Discovery of FR166124, a novel water-soluble pyrazolo-[1,5-a]pyridine adenosine A1 receptor antagonist.
AID414676Displacement of [3H]DPCPX from bovine brain cortical membrane adenosine A1 receptor2009Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8
Pyrido[2,3-e]-1,2,4-triazolo[4,3-a]pyrazin-1-one as a new scaffold to develop potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluation, and ligand-receptor modeling studies.
AID230247Ratio of Na+ to K+ excretion1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
8-(Dicyclopropylmethyl)-1,3-dipropylxanthine: a potent and selective adenosine A1 antagonist with renal protective and diuretic activities.
AID33563Binding affinity against adenosine A2 receptor using N-[3H]-ethyladenosin-5''-uronamide as radioligand in rat striatal membranes.1992Journal of medicinal chemistry, Mar-06, Volume: 35, Issue:5
8-Polycycloalkyl-1,3-dipropylxanthines as potent and selective antagonists for A1-adenosine receptors.
AID33904Adenosine A2 receptor binding using [3H]CGS-21680 in rat striatal membranes1999Journal of medicinal chemistry, Mar-11, Volume: 42, Issue:5
Discovery of 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)- pyridazinebutanoic acid (FK 838): a novel non-xanthine adenosine A1 receptor antagonist with potent diuretic activity.
AID254536Binding affinity towards human Adenosine A1 receptor expressed in CHO cells using 1 nM [3H]DPCPX2005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
AID189939Ratio of urinary excretion value (urinary volume) in treated rats to that in control rats, at a peroral dose of 6.25 mg/Kg1992Journal of medicinal chemistry, Aug-07, Volume: 35, Issue:16
Adenosine A1 antagonists. 2. Structure-activity relationships on diuretic activities and protective effects against acute renal failure.
AID33562Binding affinity against adenosine A2 receptor using N-[3H]-ethyl adenosine-5-uronamide in rat striatal membranes1992Journal of medicinal chemistry, Mar-06, Volume: 35, Issue:5
8-Polycycloalkyl-1,3-dipropylxanthines as potent and selective antagonists for A1-adenosine receptors.
AID189937Ratio of urinary excretion value (urinary volume) in treated rats to that in control rats, at a peroral dose of 25 mg/Kg1992Journal of medicinal chemistry, Aug-07, Volume: 35, Issue:16
Adenosine A1 antagonists. 2. Structure-activity relationships on diuretic activities and protective effects against acute renal failure.
AID418503Displacement of [3H]NECA from human adenosine A3 receptor expressed in CHO cells2009Bioorganic & medicinal chemistry, Apr-01, Volume: 17, Issue:7
8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands.
AID449703NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay 2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID1692736Displacement of N-[3H]ethyladenosin-5'-uronamide from adenosine receptor A2 in rat striatal membranes by liquid scintillation counting method2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Opportunities for Tapping into Three-Dimensional Chemical Space through a Quaternary Carbon.
AID231273Ratio of binding affinity against bovine adenosine A1 to that of A2 receptor2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Study on affinity profile toward native human and bovine adenosine receptors of a series of 1,8-naphthyridine derivatives.
AID266827Displacement of [3H]NECA from human adenosine A2A receptor expressed in CHO cells2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
4-amido-2-aryl-1,2,4-triazolo[4,3-a]quinoxalin-1-ones as new potent and selective human A3 adenosine receptor antagonists. synthesis, pharmacological evaluation, and ligand-receptor modeling studies.
AID188277Ratio of sodium ion/potassium ion concentration in treated rats to that in control rats, at a peroral dose of 0.1 mg/Kg1992Journal of medicinal chemistry, Aug-07, Volume: 35, Issue:16
Adenosine A1 antagonists. 2. Structure-activity relationships on diuretic activities and protective effects against acute renal failure.
AID1248377Ratio of Ki for Adenosine A1 receptor in Wistar rat brain cortical membranes in presence of GTP to Ki for Adenosine A1 receptor in Wistar rat brain cortical membranes in absence of GTP2015Bioorganic & medicinal chemistry, Oct-15, Volume: 23, Issue:20
1,3,7-Triethyl-substituted xanthines--possess nanomolar affinity for the adenosine A1 receptor.
AID188278Ratio of sodium ion/potassium ion concentration in treated rats to that in control rats, at a peroral dose of 0.4 mg/Kg1992Journal of medicinal chemistry, Aug-07, Volume: 35, Issue:16
Adenosine A1 antagonists. 2. Structure-activity relationships on diuretic activities and protective effects against acute renal failure.
AID1618058Displacement of [3H]DPCPX from human A1AR expressed in CHO cells incubated for 50 mins by radioligand binding assay2020European journal of medicinal chemistry, Feb-01, Volume: 187Identification of new potent A
AID302710Displacement of [3H]NECA from human adenosine A2A receptor expressed in CHO cells2007Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23
5-amino-2-phenyl[1,2,3]triazolo[1,2-a][1,2,4]benzotriazin-1-one: a versatile scaffold to obtain potent and selective A3 adenosine receptor antagonists.
AID763042Displacement of [3H]CGS21680 from human adenosine A2A receptor expressed in HEK293 cells after 60 mins by liquid scintillation counting analysis2013Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1
Fluorescent ligands for adenosine receptors.
AID31999Displacement of [3H]CHA from adenosine A1 receptor in bovine brain membranes2000Journal of medicinal chemistry, Aug-10, Volume: 43, Issue:16
Synthesis and structure-activity relationships of a new set of 2-arylpyrazolo[3,4-c]quinoline derivatives as adenosine receptor antagonists.
AID115116Tested for locomotor activity after oral administration of 6.25 mg/kg for 120 min1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
Adenosine A1 antagonists. 3. Structure-activity relationships on amelioration against scopolamine- or N6-((R)-phenylisopropyl)adenosine-induced cognitive disturbance.
AID266831Displacement of [3H]CGS 21680 from adenosine A2A receptor in bovine striatal membranes2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
4-amido-2-aryl-1,2,4-triazolo[4,3-a]quinoxalin-1-ones as new potent and selective human A3 adenosine receptor antagonists. synthesis, pharmacological evaluation, and ligand-receptor modeling studies.
AID1658916Displacement [3H]ZM241385 from adenosine A2A receptor in human HeLa cell membranes incubated for 30 mins by scintillation counting method2020Journal of medicinal chemistry, 07-23, Volume: 63, Issue:14
Nitrogen-Walk Approach to Explore Bioisosteric Replacements in a Series of Potent A
AID33615Displacement of [3H]-CGS- 21680 from adenosine A2a receptor of bovine striatal membrane2001Journal of medicinal chemistry, Feb-01, Volume: 44, Issue:3
3-Aryl[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-ones: a new class of selective A1 adenosine receptor antagonists.
AID31692Antagonistic activity on N6-([3H]-phenylisopropyl)adenosine binding to rat brain membrane (Adenosine A1 receptor)1988Journal of medicinal chemistry, Mar, Volume: 31, Issue:3
8-Aryl-and 8-cycloalkyl-1,3-dipropylxanthines: further potent and selective antagonists for A1-adenosine receptors.
AID1637887Selectivity index, ratio of Ki for adenosine A1 receptor in rat brain membranes in presence of GTP to Ki for adenosine A1 receptor in rat brain membranes in absence of GTP
AID33746Binding affinity against adenosine A2 receptor using [3H]- NECA as radioligand1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential.
AID763041Competitive binding affinity to human adenosine A3 receptor expressed in CHO cells after 90 mins by flow cytometric analysis in presence of MRS54492013Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1
Fluorescent ligands for adenosine receptors.
AID256818Displacement of [3H]NECA from cloned human adenosine A2A receptor expressed in CHO cells2005Journal of medicinal chemistry, Dec-15, Volume: 48, Issue:25
1,2,4-Triazolo[1,5-a]quinoxaline as a versatile tool for the design of selective human A3 adenosine receptor antagonists: synthesis, biological evaluation, and molecular modeling studies of 2-(hetero)aryl- and 2-carboxy-substituted derivatives.
AID31882Binding affinity at rat Adenosine A1 receptor in the absence of GTP2002Journal of medicinal chemistry, Apr-25, Volume: 45, Issue:9
5'-Deoxy congeners of 9-(3-amido-3-deoxy-beta-D-xylofuranosyl)-N(6)-cyclopentyladenine: new adenosine A(1) receptor antagonists and inverse agonists.
AID1174147Antiamnesic activity in Swiss albino mouse CPA-induced amnesia model assessed as time taken to enter dark compartment during retention session at 3 mg/kg, ip administered 30 mins prior to session by passive avoidance test (Rvb = 61.2 +/- 9.0 secs)2015European journal of medicinal chemistry, Jan-07, Volume: 89Further studies on pyrazolo[1',5':1,6]pyrimido[4,5-d]pyridazin-4(3H)-ones as potent and selective human A1 adenosine receptor antagonists.
AID33613Displacement of [3H]-CGS- 21680 from adenosine A2a receptor of bovine striatal membranes2004Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14
1,2,4-triazolo[4,3-a]quinoxalin-1-one moiety as an attractive scaffold to develop new potent and selective human A3 adenosine receptor antagonists: synthesis, pharmacological, and ligand-receptor modeling studies.
AID33176Binding affinity at human Adenosine A2B receptor expressed in HEK293 cells, using [125I]ABOPX as radioligand2002Journal of medicinal chemistry, May-23, Volume: 45, Issue:11
Structure-activity relationships at human and rat A2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions.
AID156510Inhibition of 5'-(N-ethylcarbamoyl)adenosine-elicited stimulation of adenylate cyclase in rat PC12 cell membranes1988Journal of medicinal chemistry, Mar, Volume: 31, Issue:3
8-Aryl-and 8-cycloalkyl-1,3-dipropylxanthines: further potent and selective antagonists for A1-adenosine receptors.
AID1819979Displacement of [3H]DPCPX from human A1 adenosine receptor expressed in CHO-K1 cells by radioligand binding assay2021Journal of medicinal chemistry, 05-27, Volume: 64, Issue:10
Development and Application of Subtype-Selective Fluorescent Antagonists for the Study of the Human Adenosine A
AID32177Binding affinity against adenosine A1 receptor using [3H]-CHA or [3H]PIA as radioligand1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential.
AID31869Binding affinity against adenosine A1 receptor in rat cortex by the displacement of [3H]cyclohexyladenosine (CHA).1991Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
1,3,8-trisubstituted xanthines. Effects of substitution pattern upon adenosine receptor A1/A2 affinity.
AID230229Inhibitory selectivity for A2 receptor in rat striatal membranes and A1 receptor in rat cortical membranes1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
Sulfur-containing 1,3-dialkylxanthine derivatives as selective antagonists at A1-adenosine receptors.
AID33752Ratio of A2 to A1.1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential.
AID170582Acquisition time in Scopolamine induced avoidance test (performed in rat) for antagonistic activity after peroral administration of 0.31 mg/kg (n=13)1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
Adenosine A1 antagonists. 3. Structure-activity relationships on amelioration against scopolamine- or N6-((R)-phenylisopropyl)adenosine-induced cognitive disturbance.
AID383542Displacement of [3H]MSX2 from rat adenosine A2A receptor2008European journal of medicinal chemistry, Mar, Volume: 43, Issue:3
Synthesis and adenosine receptor binding studies of some novel triazolothienopyrimidines.
AID30341Evaluated for binding affinity against Adenosine A1 receptor1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
A steric and electrostatic comparison of three models for the agonist/antagonist binding site on the adenosine A1 receptor.
AID1482177Displacement of [3H]DPCPX from human adenosine A2B receptor expressed in HEK293 cell membranes after 30 mins2017Journal of medicinal chemistry, 04-27, Volume: 60, Issue:8
Enantiospecific Recognition at the A
AID188282Ratio of sodium ion/potassium ion concentration in treated rats to that in control rats, at a peroral dose of 25 mg/Kg1992Journal of medicinal chemistry, Aug-07, Volume: 35, Issue:16
Adenosine A1 antagonists. 2. Structure-activity relationships on diuretic activities and protective effects against acute renal failure.
AID33934Inhibition of [3H]-CGS- 21680 binding to Adenosine A2A receptor in rat striatal homogenates.1996Journal of medicinal chemistry, Mar-01, Volume: 39, Issue:5
Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives: potent and selective A(2A) adenosine antagonists.
AID32168Binding affinity for Adenosine A1 receptor from Guinea pig membranes1997Journal of medicinal chemistry, Jun-06, Volume: 40, Issue:12
Synthesis and biological evaluation of the enantiomers of the potent and selective A1-adenosine antagonist 1,3-dipropyl-8-[2-(5,6-epoxynorbonyl)]-xanthine.
AID336465Antagonist activity at adenosine A1 receptor in rat cortical membrane assessed as reduction of [35S]GTPgammaS binding relative to control2002Journal of natural products, Oct, Volume: 65, Issue:10
Lignans isolated from valerian: identification and characterization of a new olivil derivative with partial agonistic activity at A(1) adenosine receptors.
AID481984Displacement of [3H]MSX-2 from adenosine A2A receptor in rat brain striatal membrane after 30 mins by scintillation counting2010European journal of medicinal chemistry, May, Volume: 45, Issue:5
Synthesis and theoretical studies on energetics of novel N- and O- perfluoroalkyl triazole tagged thienopyrimidines--their potential as adenosine receptor ligands.
AID118925Retention time in (R)-PIA) induced avoidance test (performed in mice) for antagonistic activity after peroral administration of 0.31 mg/kg (n=15) (P<0.005)1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
Adenosine A1 antagonists. 3. Structure-activity relationships on amelioration against scopolamine- or N6-((R)-phenylisopropyl)adenosine-induced cognitive disturbance.
AID33618Binding affinity against human A2 receptor (hA2) was measured through displacement of [3H]CGS-21680 using yeast cell membranes1999Bioorganic & medicinal chemistry letters, Aug-16, Volume: 9, Issue:16
Selective A1-adenosine receptor antagonists identified using yeast Saccharomyces cerevisiae functional assays.
AID189923Ratio of urinary excretion value (Na+ concentration) in treated rats to that in control rats, at a peroral dose of 1.6 mg/Kg1992Journal of medicinal chemistry, Aug-07, Volume: 35, Issue:16
Adenosine A1 antagonists. 2. Structure-activity relationships on diuretic activities and protective effects against acute renal failure.
AID418500Displacement of [3H]CCPA from human adenosine A1 receptor expressed in CHO cells2009Bioorganic & medicinal chemistry, Apr-01, Volume: 17, Issue:7
8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands.
AID1880699Antagonist activity at human wild type A1R expressed in CHO-K1 cells assessed as inhibition of forskolin/ NECA-stimulated cAMP accumulation by measuring NECA-mediated cAMP stimulation at 1 uM incubated with NECA for 30 mins by LANCE cAMP detection assay
AID320640Displacement of [3H]DPDPX from human adenosine A1 receptor expressed in CHO cells2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Derivatives of 4-amino-6-hydroxy-2-mercaptopyrimidine as novel, potent, and selective A3 adenosine receptor antagonists.
AID254555Binding affinity towards human Adenosine A2b receptor expressed in HEK293 cells using 5 nM [3H]DPCPX; nt=not tested2005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
AID229795Ratio of Ki against rat forebrain membrane A1 and rat striatal membrane A2 adenosine receptors1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
Adenosine A1 antagonists. 3. Structure-activity relationships on amelioration against scopolamine- or N6-((R)-phenylisopropyl)adenosine-induced cognitive disturbance.
AID1637885Selectivity index, ratio of Ki for adenosine A1 receptor in rat to Ki for adenosine A2A receptor
AID1174144Antiamnesic activity in Swiss albino mouse CPA-induced amnesia model assessed as time taken to enter dark compartment during training session at 3 mg/kg, ip administered 30 mins prior to session by passive avoidance test (Rvb = 16.6 +/- 4.1 secs)2015European journal of medicinal chemistry, Jan-07, Volume: 89Further studies on pyrazolo[1',5':1,6]pyrimido[4,5-d]pyridazin-4(3H)-ones as potent and selective human A1 adenosine receptor antagonists.
AID324663Displacement of [3H]ZM-241385 from human adenosine A2A receptor expressed in HEK293 cells2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
A new generation of adenosine receptor antagonists: from di- to trisubstituted aminopyrimidines.
AID30795Binding affinity against adenosine A2 receptor in human striatal membranes using [3H]CGS-21680 as radioligand2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Study on affinity profile toward native human and bovine adenosine receptors of a series of 1,8-naphthyridine derivatives.
AID32514Displacement of [3H]PIA from adenosine A1 receptors of rat brain membrane1994Journal of medicinal chemistry, Sep-30, Volume: 37, Issue:20
Structure-activity relationships of 1,3-dialkylxanthine derivatives at rat A3 adenosine receptors.
AID254542Binding affinity towards human Adenosine A2a receptor expressed in HEK293 cells using 6 nM [3H]CGS-216802005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
AID462287Displacement of [3H]MSX2 from adenosine A2A receptor in rat brain striatum membrane2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists.
AID33734Inhibition of the stimulation by 5'-(N-ethylcarbamoyl) adenosine of adenyl cyclase via Adenosine A2 receptor in rat PC12 membranes1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
Effects of 8-phenyl and 8-cycloalkyl substituents on the activity of mono-, di-, and trisubstituted alkylxanthines with substitution at the 1-, 3-, and 7-positions.
AID197757Effect on urinary excretion potassium and sodium after oral administration of 0.1 mg/kg to rats(potassium and sodium excretion in control rat is 0.169+/-0.018)1992Journal of medicinal chemistry, Aug-07, Volume: 35, Issue:16
Adenosine A1 antagonists. 2. Structure-activity relationships on diuretic activities and protective effects against acute renal failure.
AID30487Binding affinity against adenosine A2 receptor in bovine striatal membranes using [3H]-CGS-21,680 as radioligand2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Study on affinity profile toward native human and bovine adenosine receptors of a series of 1,8-naphthyridine derivatives.
AID191167Oral diuretic activity was measured after oral administration of 0.1 mg/kg to rats(control volume is 1.10+/-0.09)1992Journal of medicinal chemistry, Aug-07, Volume: 35, Issue:16
Adenosine A1 antagonists. 2. Structure-activity relationships on diuretic activities and protective effects against acute renal failure.
AID189927Ratio of urinary excretion value (Na+ concentration) in treated rats to that in control rats, at a peroral dose of 6.25 mg/Kg1992Journal of medicinal chemistry, Aug-07, Volume: 35, Issue:16
Adenosine A1 antagonists. 2. Structure-activity relationships on diuretic activities and protective effects against acute renal failure.
AID524796Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1248362Displacement of [3H]-DPCPX from Adenosine A1 receptor in Sprague-Dawley rat brain cortical membranes in presence of 0.1 mM GTP2015Bioorganic & medicinal chemistry, Oct-15, Volume: 23, Issue:20
1,3,7-Triethyl-substituted xanthines--possess nanomolar affinity for the adenosine A1 receptor.
AID33432Antagonistic activity against adenosine A2 receptor in rat adipocytes1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Structure-activity relationships of 8-cycloalkyl-1,3-dipropylxanthines as antagonists of adenosine receptors.
AID302711Displacement of [3H]AB-MECA from human adenosine A3 receptor expressed in CHO cells2007Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23
5-amino-2-phenyl[1,2,3]triazolo[1,2-a][1,2,4]benzotriazin-1-one: a versatile scaffold to obtain potent and selective A3 adenosine receptor antagonists.
AID1637879Displacement of [3H]NECA from adenosine A2A receptor in rat striatal membranes by radioligand competition assay
AID324669Inverse agonist activity at human adenosine A1 receptor expressed in CHO cells assessed as stimulation of forskolin-stimulated cAMP production by TR-FRET assay2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
A new generation of adenosine receptor antagonists: from di- to trisubstituted aminopyrimidines.
AID191170Oral diuretic activity was measured after oral administration of 0.4 mg/kg to rats(control volume is 0.83+/-0.08)1992Journal of medicinal chemistry, Aug-07, Volume: 35, Issue:16
Adenosine A1 antagonists. 2. Structure-activity relationships on diuretic activities and protective effects against acute renal failure.
AID118930Retention time in (R)-PIA) induced avoidance test (performed in mice) for antagonistic activity after peroral administration of 1.25 mg/kg (n=15) (P<0.01)1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
Adenosine A1 antagonists. 3. Structure-activity relationships on amelioration against scopolamine- or N6-((R)-phenylisopropyl)adenosine-induced cognitive disturbance.
AID275293Inhibitory constant against human adenosine A3 receptor2007Journal of medicinal chemistry, Jan-11, Volume: 50, Issue:1
Structure-activity relationship study of prion inhibition by 2-aminopyridine-3,5-dicarbonitrile-based compounds: parallel synthesis, bioactivity, and in vitro pharmacokinetics.
AID24457Compound administered at a dose of 6.25 mg/25 mL/kg orally to rats, urine collected for 6 hr and measured for K+ excretion.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
8-(Dicyclopropylmethyl)-1,3-dipropylxanthine: a potent and selective adenosine A1 antagonist with renal protective and diuretic activities.
AID537180Displacement of [3H]NECA from human adenosine A3 receptor expressed in HeLa cells after 180 mins2010Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22
Pyrazolo[1',5':1,6]pyrimido[4,5-d]pyridazin-4(3H)-ones as selective human A(1) adenosine receptor ligands.
AID197758Effect on urinary excretion potassium and sodium after oral administration of 0.4 mg/kg to rats(potassium and sodium excretion in control rat is 0.132+/-0.010)1992Journal of medicinal chemistry, Aug-07, Volume: 35, Issue:16
Adenosine A1 antagonists. 2. Structure-activity relationships on diuretic activities and protective effects against acute renal failure.
AID1248365Displacement of [3H]-DPCPX from Adenosine A1 receptor in Sprague-Dawley rat whole brain membranes in presence of 0.1 mM GTP2015Bioorganic & medicinal chemistry, Oct-15, Volume: 23, Issue:20
1,3,7-Triethyl-substituted xanthines--possess nanomolar affinity for the adenosine A1 receptor.
AID1289965Displacement of [3H]DPCPX from human Adenosine A1 receptor expressed in CHO cells after 60 mins2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
Discovery of Potent and Highly Selective A2B Adenosine Receptor Antagonist Chemotypes.
AID256809Displacement of [3H]CHA from adenosine A1 receptor in bovine cerebral cortical membranes2005Journal of medicinal chemistry, Dec-15, Volume: 48, Issue:25
1,2,4-Triazolo[1,5-a]quinoxaline as a versatile tool for the design of selective human A3 adenosine receptor antagonists: synthesis, biological evaluation, and molecular modeling studies of 2-(hetero)aryl- and 2-carboxy-substituted derivatives.
AID1248359Selectivity ratio of Ki for Adenosine A2A receptor in Sprague-Dawley rat striatal membranes to Ki for Adenosine A1 receptor in Sprague-Dawley rat whole brain membranes2015Bioorganic & medicinal chemistry, Oct-15, Volume: 23, Issue:20
1,3,7-Triethyl-substituted xanthines--possess nanomolar affinity for the adenosine A1 receptor.
AID1880710Cytotoxicity against human WI-38 cells assessed as cell viability incubated for 72 to 96 hrs by MTT assay
AID32292Binding affinity against adenosine A1 receptor in guinea pig forebrain membranes using N6-[3H]cyclohexyladenosine as radioligand1992Journal of medicinal chemistry, Aug-07, Volume: 35, Issue:16
Adenosine A1 antagonists. 2. Structure-activity relationships on diuretic activities and protective effects against acute renal failure.
AID383540Displacement of [3H]CCPA from rat adenosine A1 receptor2008European journal of medicinal chemistry, Mar, Volume: 43, Issue:3
Synthesis and adenosine receptor binding studies of some novel triazolothienopyrimidines.
AID1880702Displacement of CA200645 from NLuc human A1 receptor expressed in HEK293 cells assessed as inhibition constant by NanoBRET binding assay
AID320642Displacement of [125I]AB-MECA from human adenosine A3 receptor expressed in CHO cells2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Derivatives of 4-amino-6-hydroxy-2-mercaptopyrimidine as novel, potent, and selective A3 adenosine receptor antagonists.
AID32194Binding affinity towards adenosine A1 receptor in rat whole brain membranes using N6-[3H]cyclohexyladenosine1992Journal of medicinal chemistry, Aug-07, Volume: 35, Issue:16
Adenosine A1 antagonists. 2. Structure-activity relationships on diuretic activities and protective effects against acute renal failure.
AID30810Binding affinity against adenosine A2 receptor from rat striatal membranes, using N-[3H]-ethyladenosin-5''-uronamide as radioligand (in the presence of 50 nM cyclopentyl adenosine).1992Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12
(E)-1,3-dialkyl-7-methyl-8-(3,4,5-trimethoxystyryl)xanthines: potent and selective adenosine A2 antagonists.
AID775949Displacement of [125I]AB-MECA from human adenosine A3 receptor expressed in CHO cell membrane after 90 mins2013European journal of medicinal chemistry, Nov, Volume: 69Modulation of A2B adenosine receptor by 1-Benzyl-3-ketoindole derivatives.
AID197759Effect on urinary excretion potassium and sodium after oral administration of 6.25 mg/kg to rats(potassium and sodium excretion in control rat is 0.191+/-0.029)1992Journal of medicinal chemistry, Aug-07, Volume: 35, Issue:16
Adenosine A1 antagonists. 2. Structure-activity relationships on diuretic activities and protective effects against acute renal failure.
AID239212Inhibition of [3H]PSB-11 binding to adenosine A3 receptor2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Development of spin-labeled probes for adenosine receptors.
AID31983Binding affinity against adenosine A1 receptor in bovine cortical membranes using [3H]CHA as radioligand2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Study on affinity profile toward native human and bovine adenosine receptors of a series of 1,8-naphthyridine derivatives.
AID170574Acquisition time in Scopolamine induced avoidance test (performed in rat) for antagonistic activity after peroral administration of 0.02 mg/kg (n=13)1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
Adenosine A1 antagonists. 3. Structure-activity relationships on amelioration against scopolamine- or N6-((R)-phenylisopropyl)adenosine-induced cognitive disturbance.
AID297168Displacement of [3H]DPCPX from human adenosine A1 receptor expressed in CHO cells2007Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17
New 2-arylpyrazolo[3,4-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluation, and ligand-receptor modeling studies.
AID30502Binding affinity for adenosine A2 receptor using N-[3H]-ethyladenosin-5''-uronamide in guinea pig forebrain membranes1992Journal of medicinal chemistry, Sep-18, Volume: 35, Issue:19
7,8-Dihydro-8-ethyl-2-(3-noradamantyl)-4-propyl-1H-imidazo[2,1-i]purin-5(4H)-one: a potent and water-soluble adenosine A1 antagonist.
AID1637884Displacement of [3H]DPCPX from adenosine A1 receptor in rat brain membranes
AID537174Displacement of [3H]DPCPX from human adenosine A1 receptor expressed in CHO-A1 cells after 60 mins2010Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22
Pyrazolo[1',5':1,6]pyrimido[4,5-d]pyridazin-4(3H)-ones as selective human A(1) adenosine receptor ligands.
AID537178Displacement of [3H]DPCPX from human adenosine A2b receptor expressed in HEK293 cells after 30 mins2010Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22
Pyrazolo[1',5':1,6]pyrimido[4,5-d]pyridazin-4(3H)-ones as selective human A(1) adenosine receptor ligands.
AID494497Antagonist activity against human adenosine A1 receptor2010European journal of medicinal chemistry, Aug, Volume: 45, Issue:8
Insights into binding modes of adenosine A(2B) antagonists with ligand-based and receptor-based methods.
AID1618060Displacement of [3H]ZM241385 from human A2AR expressed in CHO cells after 90 mins by radioligand binding assay2020European journal of medicinal chemistry, Feb-01, Volume: 187Identification of new potent A
AID277890Activity at human adenosine A1 receptor expressed in CHO cells assessed as effect on forskolin-stimulated cAMP production at 1 uM2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists.
AID537176Displacement of [3H]ZM241385 from human adenosine A2a receptor expressed in HeLa cells after 30 mins2010Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22
Pyrazolo[1',5':1,6]pyrimido[4,5-d]pyridazin-4(3H)-ones as selective human A(1) adenosine receptor ligands.
AID235153Selectivity for A1 and A2A receptors1996Journal of medicinal chemistry, Mar-01, Volume: 39, Issue:5
Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives: potent and selective A(2A) adenosine antagonists.
AID108717Acquisition time in (R)-PIA) induced avoidance test (performed in mice) for antagonistic activity after peroral administration of 0.08 mg/kg (n=15)1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
Adenosine A1 antagonists. 3. Structure-activity relationships on amelioration against scopolamine- or N6-((R)-phenylisopropyl)adenosine-induced cognitive disturbance.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID191342Oral diuretic activity was measured after oral administration of 25 mg/kg to rats(control volume is 1.00+/-0.13)1992Journal of medicinal chemistry, Aug-07, Volume: 35, Issue:16
Adenosine A1 antagonists. 2. Structure-activity relationships on diuretic activities and protective effects against acute renal failure.
AID33587Binding affinity against adenosine A2 receptor in rat striatal membranes using N-[3H]-ethyladenosin-5''-uronamide as radioligand in the presence of 50 nM cyclopentyladenosine1992Journal of medicinal chemistry, Aug-07, Volume: 35, Issue:16
Adenosine A1 antagonists. 2. Structure-activity relationships on diuretic activities and protective effects against acute renal failure.
AID34871Displacement of [125I]ABA from human adenosine A3 receptor expressed in CHO cells1998Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21
A novel class of adenosine A3 receptor ligands. 1. 3-(2-Pyridinyl)isoquinoline derivatives.
AID230900Ratio of antagonist activity at A1 and A2 receptors1988Journal of medicinal chemistry, Mar, Volume: 31, Issue:3
8-Aryl-and 8-cycloalkyl-1,3-dipropylxanthines: further potent and selective antagonists for A1-adenosine receptors.
AID449704NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID32033Binding affinity for Adenosine A1 receptor of rat forebrain1997Journal of medicinal chemistry, Jun-06, Volume: 40, Issue:12
Synthesis and biological evaluation of the enantiomers of the potent and selective A1-adenosine antagonist 1,3-dipropyl-8-[2-(5,6-epoxynorbonyl)]-xanthine.
AID31980Affinity to A1 adenosine receptor was measured by the displacement of [3H]PIA in bovine brain cortical membrane1994Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18
8-Azaxanthine derivatives as antagonists of adenosine receptors.
AID1744264Displacement of [3H]DPCPX from human adenosine A1 receptor expressed in CHO cell membranes incubated for 60 mins by scintillation counting method2021Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1
3,4-Dihydropyrimidin-2(1
AID1336300Displacement of [3H]DPCPX from human recombinant adenosine receptor A1 expressed in CHO cells measured after 60 mins by scintillation counting method2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Structure-anticonvulsant activity studies in the group of (E)-N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CH
AID32193Binding affinity towards adenosine A1 receptor in rat forebrain membranes using N6-[3H]cyclohexyladenosine1992Journal of medicinal chemistry, Aug-07, Volume: 35, Issue:16
Adenosine A1 antagonists. 2. Structure-activity relationships on diuretic activities and protective effects against acute renal failure.
AID187956Effect on urinary excretion potassium and sodium after oral administration of 1.6 mg/kg to rats(potassium and sodium excretion in control rat is 0.193+/-0.016)1992Journal of medicinal chemistry, Aug-07, Volume: 35, Issue:16
Adenosine A1 antagonists. 2. Structure-activity relationships on diuretic activities and protective effects against acute renal failure.
AID31883Binding affinity at rat Adenosine A1 receptor in the presence of GTP2002Journal of medicinal chemistry, Apr-25, Volume: 45, Issue:9
5'-Deoxy congeners of 9-(3-amido-3-deoxy-beta-D-xylofuranosyl)-N(6)-cyclopentyladenine: new adenosine A(1) receptor antagonists and inverse agonists.
AID1880712Cytotoxicity against human HCT-116 cells assessed as cell viability incubated for 72 to 96 hrs by MTT assay
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID189921Ratio of urinary excretion value (Na+ concentration) in treated rats to that in control rats, at a peroral dose of 0.4 mg/Kg1992Journal of medicinal chemistry, Aug-07, Volume: 35, Issue:16
Adenosine A1 antagonists. 2. Structure-activity relationships on diuretic activities and protective effects against acute renal failure.
AID1248364Displacement of [3H]-DPCPX from Adenosine A1 receptor in Sprague-Dawley rat whole brain membranes in absence of GTP2015Bioorganic & medicinal chemistry, Oct-15, Volume: 23, Issue:20
1,3,7-Triethyl-substituted xanthines--possess nanomolar affinity for the adenosine A1 receptor.
AID1608209Antagonist activity at human A2BR expressed in CHO cells assessed as inhibition of NECA-stimulated cAMP production by alphascreen assay
AID30306Inhibitory activity against human A1 receptor (hA1) on membranes from yeast cells1999Bioorganic & medicinal chemistry letters, Aug-16, Volume: 9, Issue:16
Selective A1-adenosine receptor antagonists identified using yeast Saccharomyces cerevisiae functional assays.
AID33620Inhibitory activity against membranes from HEK293 cells stably expressing the human A2a receptor (hA2a)1999Bioorganic & medicinal chemistry letters, Aug-16, Volume: 9, Issue:16
Selective A1-adenosine receptor antagonists identified using yeast Saccharomyces cerevisiae functional assays.
AID566237Inhibition of human adenosine A1 receptor2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
Discovery of {1-[4-(2-{hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl}-1H-benzimidazol-1-yl)piperidin-1-yl]cyclooctyl}methanol, systemically potent novel non-peptide agonist of nociceptin/orphanin FQ receptor as analgesic for the treatment of neuropathic pain: de
AID1248363Ratio of Ki for Adenosine A1 receptor in Sprague-Dawley rat brain cortical membranes in presence of 0.1 mM GTP to Ki for Adenosine A1 receptor in Sprague-Dawley rat brain cortical membranes in absence of GTP2015Bioorganic & medicinal chemistry, Oct-15, Volume: 23, Issue:20
1,3,7-Triethyl-substituted xanthines--possess nanomolar affinity for the adenosine A1 receptor.
AID30444Binding affinity against human adenosine A1 receptor expressed in CHO cells using [3H]CHA2004Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14
1,2,4-triazolo[4,3-a]quinoxalin-1-one moiety as an attractive scaffold to develop new potent and selective human A3 adenosine receptor antagonists: synthesis, pharmacological, and ligand-receptor modeling studies.
AID1692737Selectivity ratio of Ki for Displacement of N-[3H]ethyladenosin-5'-uronamide from adenosine receptor A2 in rat striatal membranes to Ki for Displacement of N6-[3H]cyclohexyladenosine from adenosine receptor A1 in guinea pig forebrain membranes2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Opportunities for Tapping into Three-Dimensional Chemical Space through a Quaternary Carbon.
AID361544Displacement of [3H]AB-MECA from human adenosine A3 receptor expressed in HEK293 cell membrane2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
2-Amino-6-furan-2-yl-4-substituted nicotinonitriles as A2A adenosine receptor antagonists.
AID170578Acquisition time in Scopolamine induced avoidance test (performed in rat) for antagonistic activity after peroral administration of 0.08 mg/kg (n=13)1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
Adenosine A1 antagonists. 3. Structure-activity relationships on amelioration against scopolamine- or N6-((R)-phenylisopropyl)adenosine-induced cognitive disturbance.
AID21139Solubility in water at PH 7.4 in the presence of Tris.HCl buffer1988Journal of medicinal chemistry, Mar, Volume: 31, Issue:3
8-Aryl-and 8-cycloalkyl-1,3-dipropylxanthines: further potent and selective antagonists for A1-adenosine receptors.
AID230534Ratio of selectivity for A3 and A1 receptors at rat brain1994Journal of medicinal chemistry, Sep-30, Volume: 37, Issue:20
Structure-activity relationships of 1,3-dialkylxanthine derivatives at rat A3 adenosine receptors.
AID30489Affinity to A2 adenosine receptor was measured by the displacement of [3H]-CGS- 21680 in bovine brain striatal membrane1994Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18
8-Azaxanthine derivatives as antagonists of adenosine receptors.
AID775950Displacement of [3H]NECA from human adenosine A2A receptor expressed in CHO cell membrane after 90 mins2013European journal of medicinal chemistry, Nov, Volume: 69Modulation of A2B adenosine receptor by 1-Benzyl-3-ketoindole derivatives.
AID396975Displacement of [3H]DPCPX from human cloned adenosine A1 receptor expressed in CHOK1 cells by scintillation counting2009European journal of medicinal chemistry, May, Volume: 44, Issue:5
Synthesis of a series of 8-(substituted-phenyl)xanthines and a study on the effects of substitution pattern of phenyl substituents on affinity for adenosine A(1) and A(2A) receptors.
AID437481Antagonist activity at adenosine receptor A1 expressed in CHO chem3 cells assessed as cAMP accumulation2009Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23
Design, synthesis and biological evaluation of a bivalent micro opiate and adenosine A1 receptor antagonist.
AID336464Antagonist activity at adenosine A1 receptor in rat cortical membrane assessed as reduction of [35S]GTPgammaS binding2002Journal of natural products, Oct, Volume: 65, Issue:10
Lignans isolated from valerian: identification and characterization of a new olivil derivative with partial agonistic activity at A(1) adenosine receptors.
AID33740Binding affinity at Adenosine A2 receptor from rat striatal membranes by N-[3H] ethyladenosin-5'- uronamide displacement.1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
Adenosine A1 antagonists. 3. Structure-activity relationships on amelioration against scopolamine- or N6-((R)-phenylisopropyl)adenosine-induced cognitive disturbance.
AID414678Displacement of [3H]CGS 21680 from bovine striatal membrane adenosine A2A receptor2009Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8
Pyrido[2,3-e]-1,2,4-triazolo[4,3-a]pyrazin-1-one as a new scaffold to develop potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluation, and ligand-receptor modeling studies.
AID231907Ratio between the Ki values of A2 and A1 receptors1994Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18
8-Azaxanthine derivatives as antagonists of adenosine receptors.
AID228358Ratio against A1 adenosine receptor to the A2 adenosine receptor (guinea pig forebrain membranes, using N6-[3H]cyclohexyladenosine as radioligand.1992Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12
(E)-1,3-dialkyl-7-methyl-8-(3,4,5-trimethoxystyryl)xanthines: potent and selective adenosine A2 antagonists.
AID1248366Ratio of Ki for Adenosine A1 receptor in Sprague-Dawley rat whole brain membranes in presence of 0.1 mM GTP to Ki for Adenosine A1 receptor in Sprague-Dawley rat whole brain membranes in absence of GTP2015Bioorganic & medicinal chemistry, Oct-15, Volume: 23, Issue:20
1,3,7-Triethyl-substituted xanthines--possess nanomolar affinity for the adenosine A1 receptor.
AID191365Oral diuretic activity was measured after oral administration of 6.25 mg/kg to rats(control volume is 1.26+/-0.21)1992Journal of medicinal chemistry, Aug-07, Volume: 35, Issue:16
Adenosine A1 antagonists. 2. Structure-activity relationships on diuretic activities and protective effects against acute renal failure.
AID1637886Displacement of [3H]DPCPX from adenosine A1 receptor in rat brain membranes in presence of GTP by radioligand competition assay
AID1637881Selectivity index, ratio of Ki for adenosine A1 receptor in rat brain membranes to Ki for adenosine A2A receptor in rat striatal membranes
AID32294Binding affinity against Adenosine A1 receptor from guinea pig forebrain membranes by N6-[3H]- cyclohexyladenosine displacement.1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
Adenosine A1 antagonists. 3. Structure-activity relationships on amelioration against scopolamine- or N6-((R)-phenylisopropyl)adenosine-induced cognitive disturbance.
AID414674Displacement of [3H]NECA from human cloned adenosine A2A receptor expressed in CHO cells2009Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8
Pyrido[2,3-e]-1,2,4-triazolo[4,3-a]pyrazin-1-one as a new scaffold to develop potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluation, and ligand-receptor modeling studies.
AID34161KB for reversal of adenylate cyclase inhibition by (R)-N6-(2-[3H]-phenyl-1-methylethyladenosine in rat adipocytes1992Journal of medicinal chemistry, Mar-06, Volume: 35, Issue:5
8-Polycycloalkyl-1,3-dipropylxanthines as potent and selective antagonists for A1-adenosine receptors.
AID408431Displacement of [125I]DPCPX from adenosine A1 receptor in bovine brain membrane2008Bioorganic & medicinal chemistry, Jun-01, Volume: 16, Issue:11
Synthesis, ligand-receptor modeling studies and pharmacological evaluation of novel 4-modified-2-aryl-1,2,4-triazolo[4,3-a]quinoxalin-1-one derivatives as potent and selective human A3 adenosine receptor antagonists.
AID30303Binding affinity against human A1 receptor (hA1) was measured through displacement of [3H]DPCPX using yeast cell membranes1999Bioorganic & medicinal chemistry letters, Aug-16, Volume: 9, Issue:16
Selective A1-adenosine receptor antagonists identified using yeast Saccharomyces cerevisiae functional assays.
AID1248373Selectivity ratio of Ki for Adenosine A2A receptor in Wistar rat striatal membranes to Ki for Adenosine A1 receptor in Wistar rat whole brain membranes2015Bioorganic & medicinal chemistry, Oct-15, Volume: 23, Issue:20
1,3,7-Triethyl-substituted xanthines--possess nanomolar affinity for the adenosine A1 receptor.
AID414672Displacement of [3H]DPCPX from human cloned adenosine A1 receptor expressed in CHO cells2009Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8
Pyrido[2,3-e]-1,2,4-triazolo[4,3-a]pyrazin-1-one as a new scaffold to develop potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluation, and ligand-receptor modeling studies.
AID418502Antagonist activity at human adenosine A2B receptor expressed in CHO cells assessed as inhibition of NECA-stimulated adenylyl cyclase activity2009Bioorganic & medicinal chemistry, Apr-01, Volume: 17, Issue:7
8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands.
AID192857Compound was evaluated for Serum creatinine concentration in glycerol injected rats treated with 1 mg/kg administered intraperitoneally1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
8-(Dicyclopropylmethyl)-1,3-dipropylxanthine: a potent and selective adenosine A1 antagonist with renal protective and diuretic activities.
AID1482178Displacement of [3H]NECA from human adenosine A3 receptor expressed in human Hela cell membranes after 180 mins2017Journal of medicinal chemistry, 04-27, Volume: 60, Issue:8
Enantiospecific Recognition at the A
AID118937Retention time in (R)-PIA) induced avoidance test (performed in mice) for antagonistic activity after peroral administration of 5 mg/kg1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
Adenosine A1 antagonists. 3. Structure-activity relationships on amelioration against scopolamine- or N6-((R)-phenylisopropyl)adenosine-induced cognitive disturbance.
AID437485Binding affinity to mu opioid receptor2009Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23
Design, synthesis and biological evaluation of a bivalent micro opiate and adenosine A1 receptor antagonist.
AID346395Displacement of radiolabeled DPCPX from human adenosine A1 receptor2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia.
AID414974Analgesic activity in mouse assessed as reduction of formalin-induced late nociceptive behavior at 2 mg/kg, ip administered 10 mins before formalin challenge measured every 5 mins for 60 mins in presence of adenosine A1 receptor antagonist DPCPX2009Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8
N6-Cycloalkyl- and N6-bicycloalkyl-C5'(C2')-modified adenosine derivatives as high-affinity and selective agonists at the human A1 adenosine receptor with antinociceptive effects in mice.
AID449706NOVARTIS: Inhibition Frequency Index (IFI) - the number of HTS assays where a compound showed > 50% inhibition/induction, expressed as a percentage of the number of assays in which the compound was tested.2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID396976Displacement of [3H]ZM-241385 from human cloned adenosine A2A receptor expressed in HEK293 cells by scintillation counting2009European journal of medicinal chemistry, May, Volume: 44, Issue:5
Synthesis of a series of 8-(substituted-phenyl)xanthines and a study on the effects of substitution pattern of phenyl substituents on affinity for adenosine A(1) and A(2A) receptors.
AID494495Antagonist activity against human adenosine A2B receptor2010European journal of medicinal chemistry, Aug, Volume: 45, Issue:8
Insights into binding modes of adenosine A(2B) antagonists with ligand-based and receptor-based methods.
AID33728Inhibition of binding of [3H]5'-(N-ethylcarbamoyl)-adenosine to adenosine A2 receptor in rat striatal membranes1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
Sulfur-containing 1,3-dialkylxanthine derivatives as selective antagonists at A1-adenosine receptors.
AID34120Displacement of [125 I]AB-MECA from adenosine A3 receptor in bovine cortical membranes with 20 nM DPCPX2001Journal of medicinal chemistry, Feb-01, Volume: 44, Issue:3
3-Aryl[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-ones: a new class of selective A1 adenosine receptor antagonists.
AID115112Tested for locomotor activity after oral administration of 10 mg/kg for 120 min1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
Adenosine A1 antagonists. 3. Structure-activity relationships on amelioration against scopolamine- or N6-((R)-phenylisopropyl)adenosine-induced cognitive disturbance.
AID478643Displacement of [3H]DPCPX from human adenosine A1 receptor expressed in CHO cells2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Novel N2-substituted pyrazolo[3,4-d]pyrimidine adenosine A3 receptor antagonists: inhibition of A3-mediated human glioblastoma cell proliferation.
AID238978Displacement of [125I]-AB-MECA binding to human adenosine A3 receptor expressed in HEK 293 cells2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
A series of ligands displaying a remarkable agonistic-antagonistic profile at the adenosine A1 receptor.
AID33486Displacement of [125I]AB-MECA from membranes of CHO cells stably transfected with the rat adenosine A3 receptor cDNA1994Journal of medicinal chemistry, Sep-30, Volume: 37, Issue:20
Structure-activity relationships of 1,3-dialkylxanthine derivatives at rat A3 adenosine receptors.
AID33565Inhibition of [3H]5'-(N-ethylcarbamoyl)-adenosine binding to Adenosine A2 receptor in rat striatal membranes in the presence of 50 nM cyclopentyladenosine1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
8-(Dicyclopropylmethyl)-1,3-dipropylxanthine: a potent and selective adenosine A1 antagonist with renal protective and diuretic activities.
AID256849Displacement of [3H]NECA from human adenosine A2A receptor expressed in CHO cells2005Journal of medicinal chemistry, Dec-29, Volume: 48, Issue:26
2-(Benzimidazol-2-yl)quinoxalines: a novel class of selective antagonists at human A(1) and A(3) adenosine receptors designed by 3D database searching.
AID108851Acquisition time in (R)-PIA) induced avoidance test (performed in mice) for antagonistic activity after peroral administration of 5 mg/kg1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
Adenosine A1 antagonists. 3. Structure-activity relationships on amelioration against scopolamine- or N6-((R)-phenylisopropyl)adenosine-induced cognitive disturbance.
AID1375318Displacement of PSB-12105 from recombinant human adenosine A2B receptor expressed in CHO cell membranes preincubated for 30 mins followed by PSB-12105 addition measured after 20 mins by flow cytometric method2018Journal of medicinal chemistry, 05-24, Volume: 61, Issue:10
Fluorescent-Labeled Selective Adenosine A
AID33926Displacement of [3H]-CGS- 21680 from adenosine A2A receptor in bovine striatal membranes.2000Journal of medicinal chemistry, Aug-10, Volume: 43, Issue:16
Synthesis and structure-activity relationships of a new set of 2-arylpyrazolo[3,4-c]quinoline derivatives as adenosine receptor antagonists.
AID34304Inhibition of adenylate cyclase stimulation by N-[3H]-ethyladenosin-5''-uronamide in human platelet membranes1992Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12
(E)-1,3-dialkyl-7-methyl-8-(3,4,5-trimethoxystyryl)xanthines: potent and selective adenosine A2 antagonists.
AID33576Binding affinity for Adenosine A2 receptor from rat striatal membranes1997Journal of medicinal chemistry, Jun-06, Volume: 40, Issue:12
Synthesis and biological evaluation of the enantiomers of the potent and selective A1-adenosine antagonist 1,3-dipropyl-8-[2-(5,6-epoxynorbonyl)]-xanthine.
AID1822221Displacement of [3H]NECA from human A3AR expressed in HeLa cell membrane incubated for 180 mins by microbeta trilux scintillation counter analysis2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Optimization of 2-Amino-4,6-diarylpyrimidine-5-carbonitriles as Potent and Selective A
AID108723Acquisition time in (R)-PIA) induced avoidance test (performed in mice) for antagonistic activity after peroral administration of 1.25 mg/kg (n=15)1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
Adenosine A1 antagonists. 3. Structure-activity relationships on amelioration against scopolamine- or N6-((R)-phenylisopropyl)adenosine-induced cognitive disturbance.
AID256823Selectivity for human adenosine A3 receptor over human adenosine A2A receptor2005Journal of medicinal chemistry, Dec-15, Volume: 48, Issue:25
1,2,4-Triazolo[1,5-a]quinoxaline as a versatile tool for the design of selective human A3 adenosine receptor antagonists: synthesis, biological evaluation, and molecular modeling studies of 2-(hetero)aryl- and 2-carboxy-substituted derivatives.
AID661338Displacement of [3H]DPCPX from human A1 adenosine receptor expressed in CHO cell membrane2012Journal of medicinal chemistry, Feb-23, Volume: 55, Issue:4
3-aryl-[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-one: a novel template for the design of highly selective A₂B adenosine receptor antagonists.
AID197745Serum creatinine concentration measured after intraperitoneal administration of 1 mg/kg of compound to rats(vehicle 5.43+/-0.11)1992Journal of medicinal chemistry, Aug-07, Volume: 35, Issue:16
Adenosine A1 antagonists. 2. Structure-activity relationships on diuretic activities and protective effects against acute renal failure.
AID414670Displacement of [125I]AB-MECA from human cloned adenosine A3 receptor expressed in CHO cells2009Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8
Pyrido[2,3-e]-1,2,4-triazolo[4,3-a]pyrazin-1-one as a new scaffold to develop potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluation, and ligand-receptor modeling studies.
AID751905Binding affinity to human adenosine A1 receptor by radioligand displacement assay2013European journal of medicinal chemistry, May, Volume: 63Synthesis and structure-activity relationship studies in serotonin 5-HT(1A) receptor agonists based on fused pyrrolidone scaffolds.
AID229657Selectivity ratio (A3/A2B).2002Journal of medicinal chemistry, Mar-28, Volume: 45, Issue:7
1,8-disubstituted xanthine derivatives: synthesis of potent A2B-selective adenosine receptor antagonists.
AID1248372Displacement of [3H]-NECA from Adenosine A2A receptor in Wistar rat striatal membranes2015Bioorganic & medicinal chemistry, Oct-15, Volume: 23, Issue:20
1,3,7-Triethyl-substituted xanthines--possess nanomolar affinity for the adenosine A1 receptor.
AID115114Tested for locomotor activity after oral administration of 40 mg/kg for 120 min1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
Adenosine A1 antagonists. 3. Structure-activity relationships on amelioration against scopolamine- or N6-((R)-phenylisopropyl)adenosine-induced cognitive disturbance.
AID32508Tested for binding affinity against Adenosine A1 receptor from rat forebrain membranes, using N6-[3H]- cyclohexyladenosine as radioligand1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
Adenosine A1 antagonists. 3. Structure-activity relationships on amelioration against scopolamine- or N6-((R)-phenylisopropyl)adenosine-induced cognitive disturbance.
AID1608214Antagonist activity at human A2AR expressed in CHO cells assessed as inhibition of CGS21680-stimulated cAMP production by alphascreen assay
AID1744269Displacement of [3H]NECA from adenosine A3 receptor expressed in human HeLa cell membranes incubated for 180 mins by scintillation counting method2021Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1
3,4-Dihydropyrimidin-2(1
AID1174135Displacement of [3H]DPCPX from human adenosine A1 receptor expressed in CHO cells after 120 mins2015European journal of medicinal chemistry, Jan-07, Volume: 89Further studies on pyrazolo[1',5':1,6]pyrimido[4,5-d]pyridazin-4(3H)-ones as potent and selective human A1 adenosine receptor antagonists.
AID189935Ratio of urinary excretion value (urinary volume) in treated rats to that in control rats, at a peroral dose of 1.6 mg/Kg1992Journal of medicinal chemistry, Aug-07, Volume: 35, Issue:16
Adenosine A1 antagonists. 2. Structure-activity relationships on diuretic activities and protective effects against acute renal failure.
AID361540Displacement of [3H]ZM241385 from human adenosine A2A receptor expressed in HEK293 cell membrane2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
2-Amino-6-furan-2-yl-4-substituted nicotinonitriles as A2A adenosine receptor antagonists.
AID1248361Displacement of [3H]-DPCPX from Adenosine A1 receptor in Sprague-Dawley rat brain cortical membranes in absence of GTP2015Bioorganic & medicinal chemistry, Oct-15, Volume: 23, Issue:20
1,3,7-Triethyl-substituted xanthines--possess nanomolar affinity for the adenosine A1 receptor.
AID418501Displacement of [3H]NECA from human adenosine A2A receptor expressed in CHO cells2009Bioorganic & medicinal chemistry, Apr-01, Volume: 17, Issue:7
8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands.
AID34239Binding affinity for HA-tagged wild type human Adenosine A2A receptor (WT) using [3H]CGS-21680 as radioligand expressed in COS-7 cells1997Journal of medicinal chemistry, Aug-01, Volume: 40, Issue:16
Mutagenesis reveals structure-activity parallels between human A2A adenosine receptors and biogenic amine G protein-coupled receptors.
AID30625Binding affinity for Adenosine A2 receptor from Guinea pig membranes1997Journal of medicinal chemistry, Jun-06, Volume: 40, Issue:12
Synthesis and biological evaluation of the enantiomers of the potent and selective A1-adenosine antagonist 1,3-dipropyl-8-[2-(5,6-epoxynorbonyl)]-xanthine.
AID229658Selectivity ratio (A1/A2B)2002Journal of medicinal chemistry, Mar-28, Volume: 45, Issue:7
1,8-disubstituted xanthine derivatives: synthesis of potent A2B-selective adenosine receptor antagonists.
AID266825Displacement of [3H]DPCPX from human adenosine A1 receptor expressed in CHO cells2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
4-amido-2-aryl-1,2,4-triazolo[4,3-a]quinoxalin-1-ones as new potent and selective human A3 adenosine receptor antagonists. synthesis, pharmacological evaluation, and ligand-receptor modeling studies.
AID255370Selective binding affinity towards human Adenosine A1 receptor expressed in CHO cells using [3H]DPCPX compared to human Adenosine A2a receptor expressed in HEK293 cells using [3H]-CGS-21,6802005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
AID1482176Displacement of [3H]4-(2-[7-amino-2-(2-furyl)[1,2,4]triazolo[2,3-a][1,3,5]triazin-5-ylamino]ethyl)phenol from human adenosine A2A receptor expressed in human Hela cell membranes after 30 mins2017Journal of medicinal chemistry, 04-27, Volume: 60, Issue:8
Enantiospecific Recognition at the A
AID239211Inhibition of [3H]MSX-2 binding to adenosine A2a receptor2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Development of spin-labeled probes for adenosine receptors.
AID275292Inhibitory constant against human adenosine A2a receptor2007Journal of medicinal chemistry, Jan-11, Volume: 50, Issue:1
Structure-activity relationship study of prion inhibition by 2-aminopyridine-3,5-dicarbonitrile-based compounds: parallel synthesis, bioactivity, and in vitro pharmacokinetics.
AID1482175Displacement of [3H]DPCPX from human adenosine A1 receptor expressed in CHO cell membranes after 60 mins2017Journal of medicinal chemistry, 04-27, Volume: 60, Issue:8
Enantiospecific Recognition at the A
AID239265Inhibition of [3H]ZM-241,385 binding to adenosine A2b receptor2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Development of spin-labeled probes for adenosine receptors.
AID1285608Displacement of [3H]DPCPX from human recombinant adenosine A1 receptor expressed in CHO cells2016Bioorganic & medicinal chemistry, Apr-15, Volume: 24, Issue:8
Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.
AID1248371Displacement of [3H]-PIA from Adenosine A1 receptor in Wistar rat brain membranes2015Bioorganic & medicinal chemistry, Oct-15, Volume: 23, Issue:20
1,3,7-Triethyl-substituted xanthines--possess nanomolar affinity for the adenosine A1 receptor.
AID31994Displacement of [3H]CHA from adenosine A1 receptors was determined in bovine cortical membranes2001Journal of medicinal chemistry, Feb-01, Volume: 44, Issue:3
3-Aryl[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-ones: a new class of selective A1 adenosine receptor antagonists.
AID32494Inhibition of N6-[3H]cyclohexyladenosine binding to adenosine A1 receptor from whole brain membranes1992Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12
(E)-1,3-dialkyl-7-methyl-8-(3,4,5-trimethoxystyryl)xanthines: potent and selective adenosine A2 antagonists.
AID188280Ratio of sodium ion/potassium ion concentration in treated rats to that in control rats, at a peroral dose of 1.6 mg/Kg1992Journal of medicinal chemistry, Aug-07, Volume: 35, Issue:16
Adenosine A1 antagonists. 2. Structure-activity relationships on diuretic activities and protective effects against acute renal failure.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID256816Displacement of [3H]CHA from cloned human adenosine A1 receptor expressed in CHO cells2005Journal of medicinal chemistry, Dec-15, Volume: 48, Issue:25
1,2,4-Triazolo[1,5-a]quinoxaline as a versatile tool for the design of selective human A3 adenosine receptor antagonists: synthesis, biological evaluation, and molecular modeling studies of 2-(hetero)aryl- and 2-carboxy-substituted derivatives.
AID30790Inhibition of binding to membranes from HEK293 cells expressing human Adenosine A2 receptor1997Journal of medicinal chemistry, Jun-06, Volume: 40, Issue:12
Synthesis and biological evaluation of the enantiomers of the potent and selective A1-adenosine antagonist 1,3-dipropyl-8-[2-(5,6-epoxynorbonyl)]-xanthine.
AID230535Ratio of selectivity for A3 and A2a receptors at rat brain1994Journal of medicinal chemistry, Sep-30, Volume: 37, Issue:20
Structure-activity relationships of 1,3-dialkylxanthine derivatives at rat A3 adenosine receptors.
AID232495Selectivity as ratio of Ki against rat adenosine A2a and A1 receptor binding1997Journal of medicinal chemistry, Jun-06, Volume: 40, Issue:12
Synthesis and biological evaluation of the enantiomers of the potent and selective A1-adenosine antagonist 1,3-dipropyl-8-[2-(5,6-epoxynorbonyl)]-xanthine.
AID266272Displacement of [3H]CPX from human adenosine A3 receptor expressed in CHO cells2006Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12
Novel 1,3-disubstituted 8-(1-benzyl-1H-pyrazol-4-yl) xanthines: high affinity and selective A2B adenosine receptor antagonists.
AID33774Inhibitory activity against Adenosine A2a receptor using [3H]NECA in rat striatal membranes1999Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14
Discovery of FR166124, a novel water-soluble pyrazolo-[1,5-a]pyridine adenosine A1 receptor antagonist.
AID30772Inhibition of binding to membranes from HEK293 cells expressing human Adenosine A1 receptor1997Journal of medicinal chemistry, Jun-06, Volume: 40, Issue:12
Synthesis and biological evaluation of the enantiomers of the potent and selective A1-adenosine antagonist 1,3-dipropyl-8-[2-(5,6-epoxynorbonyl)]-xanthine.
AID1744262Displacement of [3H]ZM2421385 from adenosine A2A receptor expressed in human HeLa cell membranes incubated for 30 mins by scintillation counting method2021Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1
3,4-Dihydropyrimidin-2(1
AID383541Inhibition of rat adenosine A2A receptor upto 1 uM2008European journal of medicinal chemistry, Mar, Volume: 43, Issue:3
Synthesis and adenosine receptor binding studies of some novel triazolothienopyrimidines.
AID1658918Displacement [3H]DPCPX from human adenosine A2B receptor expressed in HEK293 cell membranes incubated for 60 mins by scintillation counting method2020Journal of medicinal chemistry, 07-23, Volume: 63, Issue:14
Nitrogen-Walk Approach to Explore Bioisosteric Replacements in a Series of Potent A
AID32164Inhibition of [3H]cyclohexyladenosine binding to guinea pig forebrain membranes Adenosine A1 receptor1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
8-(Dicyclopropylmethyl)-1,3-dipropylxanthine: a potent and selective adenosine A1 antagonist with renal protective and diuretic activities.
AID32642Relative affinities for rat Adenosine A1 and Adenosine A2B receptors2002Journal of medicinal chemistry, May-23, Volume: 45, Issue:11
Structure-activity relationships at human and rat A2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions.
AID32163Binding affinity against adenosine A1 receptor using N6-[3H]cyclohexyladenosine as radioligand in guinea pig forebrain membranes1992Journal of medicinal chemistry, Mar-06, Volume: 35, Issue:5
8-Polycycloalkyl-1,3-dipropylxanthines as potent and selective antagonists for A1-adenosine receptors.
AID763043Competitive binding affinity to human adenosine A2A receptor expressed in HEK293 cells after 60 mins by fluorescence polarization assay in presence of MRS53462013Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1
Fluorescent ligands for adenosine receptors.
AID30447Binding affinity at human Adenosine A1 receptor expressed in CHO cells2002Journal of medicinal chemistry, Apr-25, Volume: 45, Issue:9
5'-Deoxy congeners of 9-(3-amido-3-deoxy-beta-D-xylofuranosyl)-N(6)-cyclopentyladenine: new adenosine A(1) receptor antagonists and inverse agonists.
AID24459Compound administered at a dose of 6.25 mg/25 mL/kg orally to rats, urine collected for 6 hr and measured for urine volume.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
8-(Dicyclopropylmethyl)-1,3-dipropylxanthine: a potent and selective adenosine A1 antagonist with renal protective and diuretic activities.
AID238847Displacement of [3H]DPCPX binding to human adenosine A1 receptor expressed in CHO cells2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
A series of ligands displaying a remarkable agonistic-antagonistic profile at the adenosine A1 receptor.
AID30339Adenosine A1 receptor binding using [3H]DPCPX in rat cortical membranes1999Journal of medicinal chemistry, Mar-11, Volume: 42, Issue:5
Discovery of 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)- pyridazinebutanoic acid (FK 838): a novel non-xanthine adenosine A1 receptor antagonist with potent diuretic activity.
AID33417Binding affinity against adenosine A2 receptor using N-[3H]-ethyl adenosine-5-uronamide in rat striatal membranes1992Journal of medicinal chemistry, Mar-06, Volume: 35, Issue:5
8-Polycycloalkyl-1,3-dipropylxanthines as potent and selective antagonists for A1-adenosine receptors.
AID462290Displacement of [3H]PSB-603 from human adenosine A2B receptor expressed in CHO cells2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists.
AID437483Binding affinity to adenosine receptor A12009Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23
Design, synthesis and biological evaluation of a bivalent micro opiate and adenosine A1 receptor antagonist.
AID238923Displacement of [3H]-ZM 241385 binding to human adenosine A2A receptor expressed in CHO cells2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
A series of ligands displaying a remarkable agonistic-antagonistic profile at the adenosine A1 receptor.
AID1608208Agonist activity at human A2B expressed in CHO cells assessed as stimulation of cAMP production at 1 uM by alphascreen assay relative to NECA
AID1248358Displacement of [3H]-DPCPX from Adenosine A1 receptor in Sprague-Dawley rat whole brain membranes2015Bioorganic & medicinal chemistry, Oct-15, Volume: 23, Issue:20
1,3,7-Triethyl-substituted xanthines--possess nanomolar affinity for the adenosine A1 receptor.
AID239176Inhibition of [3H]CCPA binding to adenosine A1 receptor2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Development of spin-labeled probes for adenosine receptors.
AID33610Inhibition of [125I]-APOBX binding to rat Adenosine A2B receptor expressed in HEK cells2002Journal of medicinal chemistry, May-23, Volume: 45, Issue:11
Structure-activity relationships at human and rat A2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions.
AID170592Acquisition time in Scopolamine induced avoidance test (performed in rat) for antagonistic activity after peroral administration of 5 mg/kg1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
Adenosine A1 antagonists. 3. Structure-activity relationships on amelioration against scopolamine- or N6-((R)-phenylisopropyl)adenosine-induced cognitive disturbance.
AID1174137Displacement of [3H]NECA from human adenosine A2A receptor expressed in CHO cells after 120 mins2015European journal of medicinal chemistry, Jan-07, Volume: 89Further studies on pyrazolo[1',5':1,6]pyrimido[4,5-d]pyridazin-4(3H)-ones as potent and selective human A1 adenosine receptor antagonists.
AID224014Inhibition of the effects of NECA on ADP (5 uM)-induced rabbit platelet aggregation.1996Journal of medicinal chemistry, Mar-01, Volume: 39, Issue:5
Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives: potent and selective A(2A) adenosine antagonists.
AID266823Displacement of [125I]AB-MECA from human adenosine A3 receptor expressed in CHO cells2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
4-amido-2-aryl-1,2,4-triazolo[4,3-a]quinoxalin-1-ones as new potent and selective human A3 adenosine receptor antagonists. synthesis, pharmacological evaluation, and ligand-receptor modeling studies.
AID320641Displacement of [3H]NECA from human adenosine A2A receptor expressed in CHO cells2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Derivatives of 4-amino-6-hydroxy-2-mercaptopyrimidine as novel, potent, and selective A3 adenosine receptor antagonists.
AID32485Inhibition of (R)-N6-([3H]-phenylisopropyl) adenosine binding to adenosine A1 receptor from rat cortical membranes1992Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12
(E)-1,3-dialkyl-7-methyl-8-(3,4,5-trimethoxystyryl)xanthines: potent and selective adenosine A2 antagonists.
AID30336pA2 against rat brain adenosine A1 receptor1998Bioorganic & medicinal chemistry letters, Mar-17, Volume: 8, Issue:6
Diimidazo[1,2-c:4',5'-e]pyrimidines: adenosine agonist activity demonstrated by microphysiometry.
AID31694Binding affinity against adenosine A1 receptor N-[3H]cyclohexyladenosine in rat cortical membranes1992Journal of medicinal chemistry, Mar-06, Volume: 35, Issue:5
8-Polycycloalkyl-1,3-dipropylxanthines as potent and selective antagonists for A1-adenosine receptors.
AID1289971Displacement of [3H]NECA from human Adenosine A3 receptor expressed in HeLa cells after 30 mins2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
Discovery of Potent and Highly Selective A2B Adenosine Receptor Antagonist Chemotypes.
AID478645Displacement of [125I]AB-MECA from human adenosine A3 receptor expressed in CHO cells2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Novel N2-substituted pyrazolo[3,4-d]pyrimidine adenosine A3 receptor antagonists: inhibition of A3-mediated human glioblastoma cell proliferation.
AID21650Partition coefficient of the compound1999Bioorganic & medicinal chemistry letters, Aug-16, Volume: 9, Issue:16
Selective A1-adenosine receptor antagonists identified using yeast Saccharomyces cerevisiae functional assays.
AID32481GTP-induced shift at rat Adenosine A1 receptor (A1AR)2002Journal of medicinal chemistry, Apr-25, Volume: 45, Issue:9
5'-Deoxy congeners of 9-(3-amido-3-deoxy-beta-D-xylofuranosyl)-N(6)-cyclopentyladenine: new adenosine A(1) receptor antagonists and inverse agonists.
AID231277Ratio of binding affinity against human adenosine A1 to that of A2 receptor2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Study on affinity profile toward native human and bovine adenosine receptors of a series of 1,8-naphthyridine derivatives.
AID340231Inhibition of human adenosine A1 receptor2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity.
AID1289967Displacement of [3H]ZM241385 from human Adenosine A2A receptor expressed in HeLa cells after 30 mins2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
Discovery of Potent and Highly Selective A2B Adenosine Receptor Antagonist Chemotypes.
AID32487Inhibition of 1 nM [3H]- N6 -(phenylisopropyl) adenosine binding to Adenosine A1 receptor in rat fat cell membrane1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
Effects of 8-phenyl and 8-cycloalkyl substituents on the activity of mono-, di-, and trisubstituted alkylxanthines with substitution at the 1-, 3-, and 7-positions.
AID297170Displacement of [3H]NECA from human adenosine A2A receptor expressed in CHO cells2007Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17
New 2-arylpyrazolo[3,4-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluation, and ligand-receptor modeling studies.
AID32350Inhibition of [3H]-CHA binding to Adenosine A1 receptor in rat whole brain homogenates.1996Journal of medicinal chemistry, Mar-01, Volume: 39, Issue:5
Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives: potent and selective A(2A) adenosine antagonists.
AID414973Analgesic activity in mouse assessed as reduction of formalin-induced early nociceptive behavior at 2 mg/kg, ip administered 10 mins before formalin challenge measured every 5 mins for 60 mins in presence of adenosine A1 receptor antagonist DPCPX2009Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8
N6-Cycloalkyl- and N6-bicycloalkyl-C5'(C2')-modified adenosine derivatives as high-affinity and selective agonists at the human A1 adenosine receptor with antinociceptive effects in mice.
AID188407Ratio of sodium ion/potassium ion concentration in urine of rats following 6.25 mg/kg p.o.1992Journal of medicinal chemistry, Aug-07, Volume: 35, Issue:16
Adenosine A1 antagonists. 2. Structure-activity relationships on diuretic activities and protective effects against acute renal failure.
AID189933Ratio of urinary excretion value (urinary volume) in treated rats to that in control rats, at a peroral dose of 0.4 mg/Kg1992Journal of medicinal chemistry, Aug-07, Volume: 35, Issue:16
Adenosine A1 antagonists. 2. Structure-activity relationships on diuretic activities and protective effects against acute renal failure.
AID1608203Displacement of [3H]ZM241385 from human A2AR expressed in CHO cell membranes measured after 60 mins by scintillation counting method
AID361538Displacement of [3H]DPCPX from human adenosine A1 receptor expressed in CHO cell membrane2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
2-Amino-6-furan-2-yl-4-substituted nicotinonitriles as A2A adenosine receptor antagonists.
AID763040Displacement of [125I]I-AB-MECA from human adenosine A3 receptor expressed in CHO cells after 90 mins by gamma counting analysis2013Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1
Fluorescent ligands for adenosine receptors.
AID1608201Displacement of [3H]DPCPX from human A1AR expressed in CHO cell membranes measured after 90 mins by scintillation counting method
AID34238Binding affinity for HA-tagged mutant human Adenosine A2A receptor (V84L), using [3H]CGS-21680 as radioligand expressed in COS-7 cells1997Journal of medicinal chemistry, Aug-01, Volume: 40, Issue:16
Mutagenesis reveals structure-activity parallels between human A2A adenosine receptors and biogenic amine G protein-coupled receptors.
AID189925Ratio of urinary excretion value (Na+ concentration) in treated rats to that in control rats, at a peroral dose of 25 mg/Kg1992Journal of medicinal chemistry, Aug-07, Volume: 35, Issue:16
Adenosine A1 antagonists. 2. Structure-activity relationships on diuretic activities and protective effects against acute renal failure.
AID32865Binding affinity at rat Adenosine A2A receptor by [3H]-CGS- 21680 displacement.2002Journal of medicinal chemistry, May-23, Volume: 45, Issue:11
Structure-activity relationships at human and rat A2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions.
AID33940Displacement of [3H]-CGS- 21680 from adenosine A2a receptors of rat striatal membrane1994Journal of medicinal chemistry, Sep-30, Volume: 37, Issue:20
Structure-activity relationships of 1,3-dialkylxanthine derivatives at rat A3 adenosine receptors.
AID256813Displacement of [3H]CGS 21680 from adenosine A2A receptor in bovine striatal membranes2005Journal of medicinal chemistry, Dec-15, Volume: 48, Issue:25
1,2,4-Triazolo[1,5-a]quinoxaline as a versatile tool for the design of selective human A3 adenosine receptor antagonists: synthesis, biological evaluation, and molecular modeling studies of 2-(hetero)aryl- and 2-carboxy-substituted derivatives.
AID189920Ratio of urinary excretion value (Na+ concentration) in treated rats to that in control rats, at a peroral dose of 0.1 mg/Kg1992Journal of medicinal chemistry, Aug-07, Volume: 35, Issue:16
Adenosine A1 antagonists. 2. Structure-activity relationships on diuretic activities and protective effects against acute renal failure.
AID1692735Displacement of N6-[3H]cyclohexyladenosine from adenosine receptor A1 in guinea pig forebrain membranes by liquid scintillation counting method2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Opportunities for Tapping into Three-Dimensional Chemical Space through a Quaternary Carbon.
AID1637883Displacement of [3H]DPCPX from adenosine A2A receptor in rat striatal membranes
AID1248367Inhibition of CPA-induced hypolocomotion in Sprague-Dawley rat at 0.03 to 0.1 mg/kg, ip administered 25 mins prior to CPA addition measured for 20 mins starting from 5 mins post habituation2015Bioorganic & medicinal chemistry, Oct-15, Volume: 23, Issue:20
1,3,7-Triethyl-substituted xanthines--possess nanomolar affinity for the adenosine A1 receptor.
AID31105Forskolin-induced cAMP production at human Adenosine A1 receptor2002Journal of medicinal chemistry, Apr-25, Volume: 45, Issue:9
5'-Deoxy congeners of 9-(3-amido-3-deoxy-beta-D-xylofuranosyl)-N(6)-cyclopentyladenine: new adenosine A(1) receptor antagonists and inverse agonists.
AID775951Displacement of [3H]DPCPX from human adenosine A1 receptor expressed in CHO cell membrane after 180 mins2013European journal of medicinal chemistry, Nov, Volume: 69Modulation of A2B adenosine receptor by 1-Benzyl-3-ketoindole derivatives.
AID1822217Displacement of [3H]HZ241385 from human A2AAR expressed in HeLa cell membrane incubated for 30 mins by microbeta trilux scintillation counter analysis2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Optimization of 2-Amino-4,6-diarylpyrimidine-5-carbonitriles as Potent and Selective A
AID1248369Displacement of [3H]-DPCPX from Adenosine A1 receptor in rat whole brain membranes2015Bioorganic & medicinal chemistry, Oct-15, Volume: 23, Issue:20
1,3,7-Triethyl-substituted xanthines--possess nanomolar affinity for the adenosine A1 receptor.
AID1658914Displacement [3H]DPCPX from human adenosine A1 receptor expressed in CHO cell membranes incubated for 60 mins by scintillation counting method2020Journal of medicinal chemistry, 07-23, Volume: 63, Issue:14
Nitrogen-Walk Approach to Explore Bioisosteric Replacements in a Series of Potent A
AID1248360Displacement of [3H]-NECA from Adenosine A2A receptor in Sprague-Dawley rat striatal membranes2015Bioorganic & medicinal chemistry, Oct-15, Volume: 23, Issue:20
1,3,7-Triethyl-substituted xanthines--possess nanomolar affinity for the adenosine A1 receptor.
AID191561Retention time in Scopolamine induced avoidance test (performed in rat) for antagonistic activity after peroral administration of 0.31 mg/kg (n=13) (P<0.005)1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
Adenosine A1 antagonists. 3. Structure-activity relationships on amelioration against scopolamine- or N6-((R)-phenylisopropyl)adenosine-induced cognitive disturbance.
AID118922Retention time in (R)-PIA) induced avoidance test (performed in mice) for antagonistic activity after peroral administration of 0.08 mg/kg (n=15) (P<0.01)1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
Adenosine A1 antagonists. 3. Structure-activity relationships on amelioration against scopolamine- or N6-((R)-phenylisopropyl)adenosine-induced cognitive disturbance.
AID33744Ratio of Ki for binding to A2 and A1 receptors1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
8-(Dicyclopropylmethyl)-1,3-dipropylxanthine: a potent and selective adenosine A1 antagonist with renal protective and diuretic activities.
AID1608205Displacement of [125I]ABMECA from human A3R expressed in CHO cell membranes measured after 120 mins by scintillation counting method
AID170585Acquisition time in Scopolamine induced avoidance test (performed in rat) for antagonistic activity after peroral administration of 1.25 mg/kg1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
Adenosine A1 antagonists. 3. Structure-activity relationships on amelioration against scopolamine- or N6-((R)-phenylisopropyl)adenosine-induced cognitive disturbance.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1345822Human A3 receptor (Adenosine receptors)2006ChemMedChem, Aug, Volume: 1, Issue:8
Improving potency, selectivity, and water solubility of adenosine A1 receptor antagonists: xanthines modified at position 3 and related pyrimido[1,2,3-cd]purinediones.
AID1345822Human A3 receptor (Adenosine receptors)1993Proceedings of the National Academy of Sciences of the United States of America, Nov-01, Volume: 90, Issue:21
Molecular cloning and characterization of the human A3 adenosine receptor.
AID1345721Human A2B receptor (Adenosine receptors)2005The Journal of pharmacology and experimental therapeutics, Oct, Volume: 315, Issue:1
A novel A1 adenosine receptor antagonist, L-97-1 [3-[2-(4-aminophenyl)-ethyl]-8-benzyl-7-{2-ethyl-(2-hydroxy-ethyl)-amino]-ethyl}-1-propyl-3,7-dihydro-purine-2,6-dione], reduces allergic responses to house dust mite in an allergic rabbit model of asthma.
AID1345618Human A2A receptor (Adenosine receptors)1998Naunyn-Schmiedeberg's archives of pharmacology, Jan, Volume: 357, Issue:1
Comparative pharmacology of human adenosine receptor subtypes - characterization of stably transfected receptors in CHO cells.
AID1345831Rat A3 receptor (Adenosine receptors)2006ChemMedChem, Aug, Volume: 1, Issue:8
Improving potency, selectivity, and water solubility of adenosine A1 receptor antagonists: xanthines modified at position 3 and related pyrimido[1,2,3-cd]purinediones.
AID1345721Human A2B receptor (Adenosine receptors)2006ChemMedChem, Aug, Volume: 1, Issue:8
Improving potency, selectivity, and water solubility of adenosine A1 receptor antagonists: xanthines modified at position 3 and related pyrimido[1,2,3-cd]purinediones.
AID1345685Human A1 receptor (Adenosine receptors)1999The Journal of biological chemistry, Feb-05, Volume: 274, Issue:6
Identification of the adenine binding site of the human A1 adenosine receptor.
AID1345740Rat A2B receptor (Adenosine receptors)2002Journal of medicinal chemistry, May-23, Volume: 45, Issue:11
Structure-activity relationships at human and rat A2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions.
AID1345740Rat A2B receptor (Adenosine receptors)2003European journal of pharmacology, Aug-15, Volume: 475, Issue:1-3
Antagonist pharmacology of adenosine A2B receptors from rat, guinea pig and dog.
AID1345685Human A1 receptor (Adenosine receptors)2006ChemMedChem, Aug, Volume: 1, Issue:8
Improving potency, selectivity, and water solubility of adenosine A1 receptor antagonists: xanthines modified at position 3 and related pyrimido[1,2,3-cd]purinediones.
AID1345618Human A2A receptor (Adenosine receptors)1999Biochemical pharmacology, Jan-01, Volume: 57, Issue:1
Differences in the order of potency for agonists but not antagonists at human and rat adenosine A2A receptors.
AID1345685Human A1 receptor (Adenosine receptors)2005European journal of pharmacology, Mar-07, Volume: 510, Issue:1-2
A "locked-on," constitutively active mutant of the adenosine A1 receptor.
AID1345822Human A3 receptor (Adenosine receptors)1997Molecular pharmacology, Nov, Volume: 52, Issue:5
Canine mast cell adenosine receptors: cloning and expression of the A3 receptor and evidence that degranulation is mediated by the A2B receptor.
AID1345630Rat A1 receptor (Adenosine receptors)2002Journal of medicinal chemistry, May-23, Volume: 45, Issue:11
Structure-activity relationships at human and rat A2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions.
AID1345690Rat A2A receptor (Adenosine receptors)2000European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, , Volume: 10, Issue:4
Binding of [3H]MSX-2 (3-(3-hydroxypropyl)-7-methyl-8-(m-methoxystyryl)-1-propargylxanthine) to rat striatal membranes--a new, selective antagonist radioligand for A(2A) adenosine receptors.
AID1345831Rat A3 receptor (Adenosine receptors)1994The Journal of biological chemistry, Oct-07, Volume: 269, Issue:40
Role of the second extracellular loop of adenosine receptors in agonist and antagonist binding. Analysis of chimeric A1/A3 adenosine receptors.
AID1345721Human A2B receptor (Adenosine receptors)2004Biochemical pharmacology, Jul-15, Volume: 68, Issue:2
[3H]OSIP339391, a selective, novel, and high affinity antagonist radioligand for adenosine A2B receptors.
AID1345822Human A3 receptor (Adenosine receptors)2000Molecular pharmacology, May, Volume: 57, Issue:5
[(3)H]MRE 3008F20: a novel antagonist radioligand for the pharmacological and biochemical characterization of human A(3) adenosine receptors.
AID1345822Human A3 receptor (Adenosine receptors)1998Naunyn-Schmiedeberg's archives of pharmacology, Jan, Volume: 357, Issue:1
Comparative pharmacology of human adenosine receptor subtypes - characterization of stably transfected receptors in CHO cells.
AID1345630Rat A1 receptor (Adenosine receptors)2006ChemMedChem, Aug, Volume: 1, Issue:8
Improving potency, selectivity, and water solubility of adenosine A1 receptor antagonists: xanthines modified at position 3 and related pyrimido[1,2,3-cd]purinediones.
AID1345822Human A3 receptor (Adenosine receptors)2002Journal of medicinal chemistry, Mar-28, Volume: 45, Issue:7
1,8-disubstituted xanthine derivatives: synthesis of potent A2B-selective adenosine receptor antagonists.
AID1345618Human A2A receptor (Adenosine receptors)1999Naunyn-Schmiedeberg's archives of pharmacology, Jan, Volume: 359, Issue:1
Comparison of CGS 15943, ZM 241385 and SCH 58261 as antagonists at human adenosine receptors.
AID1345630Rat A1 receptor (Adenosine receptors)1991Naunyn-Schmiedeberg's archives of pharmacology, Feb, Volume: 343, Issue:2
Comparison of A1 adenosine receptors in brain from different species by radioligand binding and photoaffinity labelling.
AID1345831Rat A3 receptor (Adenosine receptors)1997Molecular pharmacology, Nov, Volume: 52, Issue:5
Canine mast cell adenosine receptors: cloning and expression of the A3 receptor and evidence that degranulation is mediated by the A2B receptor.
AID1345735Mouse A2B receptor (Adenosine receptors)2009The Journal of pharmacology and experimental therapeutics, Apr, Volume: 329, Issue:1
Characterization of the A2B adenosine receptor from mouse, rabbit, and dog.
AID1345721Human A2B receptor (Adenosine receptors)2002Journal of medicinal chemistry, May-23, Volume: 45, Issue:11
Structure-activity relationships at human and rat A2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions.
AID1345685Human A1 receptor (Adenosine receptors)1994British journal of pharmacology, Apr, Volume: 111, Issue:4
Coupling of a transfected human brain A1 adenosine receptor in CHO-K1 cells to calcium mobilisation via a pertussis toxin-sensitive mechanism.
AID1345690Rat A2A receptor (Adenosine receptors)2002Journal of medicinal chemistry, May-23, Volume: 45, Issue:11
Structure-activity relationships at human and rat A2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions.
AID1345618Human A2A receptor (Adenosine receptors)1997British journal of pharmacology, Jun, Volume: 121, Issue:3
Characterization of human A2A adenosine receptors with the antagonist radioligand [3H]-SCH 58261.
AID1345618Human A2A receptor (Adenosine receptors)2006ChemMedChem, Aug, Volume: 1, Issue:8
Improving potency, selectivity, and water solubility of adenosine A1 receptor antagonists: xanthines modified at position 3 and related pyrimido[1,2,3-cd]purinediones.
AID1345685Human A1 receptor (Adenosine receptors)2005The Journal of pharmacology and experimental therapeutics, Oct, Volume: 315, Issue:1
A novel A1 adenosine receptor antagonist, L-97-1 [3-[2-(4-aminophenyl)-ethyl]-8-benzyl-7-{2-ethyl-(2-hydroxy-ethyl)-amino]-ethyl}-1-propyl-3,7-dihydro-purine-2,6-dione], reduces allergic responses to house dust mite in an allergic rabbit model of asthma.
AID1798054Receptor Binding Assay from Article 10.1021/jm701187w: \\2-Amino-N-pyrimidin-4-ylacetamides as A2A Receptor Antagonists: 2. Reduction of hERG Activity, Observed Species Selectivity, and Structure-Activity Relationships.\\2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
2-Amino-N-pyrimidin-4-ylacetamides as A2A receptor antagonists: 2. Reduction of hERG activity, observed species selectivity, and structure-activity relationships.
AID1798061Human A1 Adenosine Receptor Binding Assay from Article 10.1021/jm701159t: \\Derivatives of 4-Amino-6-hydroxy-2-mercaptopyrimidine as Novel, Potent, and Selective A3 Adenosine Receptor Antagonists.\\2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Derivatives of 4-amino-6-hydroxy-2-mercaptopyrimidine as novel, potent, and selective A3 adenosine receptor antagonists.
AID1802052A2A Adenosine Receptor Binding Assay from Article 10.1111/cbdd.12801: \\4-amino-6-alkyloxy-2-alkylthiopyrimidine derivatives as novel non-nucleoside agonists for the adenosine A1 receptor.\\2016Chemical biology & drug design, 11, Volume: 88, Issue:5
4-amino-6-alkyloxy-2-alkylthiopyrimidine derivatives as novel non-nucleoside agonists for the adenosine A
AID1802053A3 Adenosine Receptor Binding Assay from Article 10.1111/cbdd.12801: \\4-amino-6-alkyloxy-2-alkylthiopyrimidine derivatives as novel non-nucleoside agonists for the adenosine A1 receptor.\\2016Chemical biology & drug design, 11, Volume: 88, Issue:5
4-amino-6-alkyloxy-2-alkylthiopyrimidine derivatives as novel non-nucleoside agonists for the adenosine A
AID1798052Receptor Binding Assay from Article 10.1021/jm701185v: \\2-Amino-N-pyrimidin-4-ylacetamides as A2A Receptor Antagonists: 1. Structure-Activity Relationships and Optimization of Heterocyclic Substituents.\\2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
2-Amino-N-pyrimidin-4-ylacetamides as A2A receptor antagonists: 1. Structure-activity relationships and optimization of heterocyclic substituents.
AID1802051A1 Adenosine Receptor Binding Assay from Article 10.1111/cbdd.12801: \\4-amino-6-alkyloxy-2-alkylthiopyrimidine derivatives as novel non-nucleoside agonists for the adenosine A1 receptor.\\2016Chemical biology & drug design, 11, Volume: 88, Issue:5
4-amino-6-alkyloxy-2-alkylthiopyrimidine derivatives as novel non-nucleoside agonists for the adenosine A
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID602156Novartis GNF Liver Stage Dataset: Malariabox Annotation2011Science (New York, N.Y.), Dec-09, Volume: 334, Issue:6061
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,281)

TimeframeStudies, This Drug (%)All Drugs %
pre-199026 (2.03)18.7374
1990's526 (41.06)18.2507
2000's516 (40.28)29.6817
2010's188 (14.68)24.3611
2020's25 (1.95)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 8.85

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index8.85 (24.57)
Research Supply Index7.17 (2.92)
Research Growth Index6.02 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (8.85)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.08%)5.53%
Reviews8 (0.61%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other1,292 (99.31%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]